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Pulmonary hypertension (PH) is a progressive life-threatening vasculopathy characterized by 
dysregulated pulmonary vascular remodelling that results in an increased pulmonary vascular 
resistance, right ventricular hypertrophy, right heart failure and untimely death. Human 
Immunodeficiency virus (HIV) is a recognized cause of PH with a relatively stable prevalence of 
HIV associated PH of 0.5% in most developed countries. One of the animal models of PH is 
comprises a once off monocrotaline (MCT) in rats, which leads to PH that mimics typical PH 
presentation observed in humans. Early administration of antiretroviral medication has been shown 
to prevent the development of PH in human subjects, however, in advanced cases no significant 
improvement was reported. The impact of antiretroviral medications is controversial; however, 
nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI) have been shown to 
improve outcome in PH animal models. A potential connection between combination antiretroviral 
and PH in human subjects has been established which was contrary the protective effects of solely 
administer NRTI. The study was conducted to test the hypothesis that antiretroviral medications 
could ameliorate MCT induced PH in rat models and identify potential biomarker for PH. 
 
An approval was given by the Animal Research Ethics Committee of the institution 
(AREC/066/018M) of University of KwaZulu-Natal, Durban, South Africa, to conduct the study. 
Forty adult male Sprague-Dawley rats (body weight: 200-250 g) were randomly divided into five 
groups (n=8 per group). The treatment groups received a single intraperitoneal injection of MCT 
(60 mg kg-1) while the control group received an equivalent volume of intraperitoneal saline 
injection. Zidovudine (100 mg kg-1), ritonavir (30 mg kg-1), or combination of both drugs 
(zidovudine 100 mg kg-1 and ritonavir 30 mg kg-1) were administrated daily for the study period of 
28 days to the rats in three of the four groups with MCT for 28 days respectively. On the twenty- 
eighth day of the study, rats were sacrificed, and the harvested lungs and hearts organ were 
analyzed. Gene expression was conducted using RT-PCR for the antioxidant’s enzymes, ASK-1 
and a laboratory assay for lipid peroxidation was performed. 
 
A significantly higher mRNA gene expression of catalase, superoxide dismutase, and glutathione 
peroxidase in the heart tissue of the antiretroviral treated rats was observed and compared to the 
untreated groups. There was an increase in malondialdehyde (MDA) in the heart tissues of untreated 
rats (37.01±1.16 nmol/g, p<0.0001) compared to the control group (3.46±0.97 nmol/g) with an 
associated reduction in MDA by the antiretrovirals. Furthermore, an increase in the total antioxidant 
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capacity (TAC) in AZT (0.85±0.02 nmol/g, p<0.0001), RTV (0.63±0.03 nmol/g, p<0.0001) and 
combination of AZT/RTV (0.77±0.06 nmol/g, p<0.0001) compared to untreated (0.28±0.025) rats. 
 
Furthermore, lower relative mRNA gene expression of ASK-1 was observed in the heart of the 
treated rats with zidovudine (2.67 ± 0.09, p < 0.0001), ritonavir (2.57 ±0.11, p < 0.0001) and a 
combination of both (2.75 ± 0.06, p < 0.0001) when compared to rats in the untreated group. An 
overexpressed mRNA gene of ASK-1 in the untreated rats (12.0 ± 0.90, p < 0.0001) when compared 
to the control. 
 
This study shows evidence that zidovudine and ritonavir ameliorate MCT-induced PH in rats by 
suppressing oxidative stress. Also, ASK-1 is a potential biomarker for anti-apoptotic characteristics 
of PH. Our findings indicate the antioxidative role of antiretroviral medications in PH and the role 









I-Pulmonary hypertension iyi-vasculopathy esongela impilo eqhubekayo ebonakala ngokuqina 
kokuqina kwemithambo yemithambo yegazi ephumela ekuphikeni kokuqina kwemithambo ye- 
pulmonary vascular, hypertrophy yesibindi, ukungaphumeleli kwenhliziyo nokuhluleka kokufa 
okungazelelwe. Igciwane lengculazi i-Human Immunodeficiency virus (i-HIV) liyimbangela 
eyaziwayo yomfutho we-pulmonary hypertension (PH) ngokuqina okuzinzile kwe-PH ehlobene ne- 
HIV ka-0.5% emazweni amaningi athuthukile. Imodeli yezilwane ye-PH yathuthukiswa ngokufaka 
amagundane ku-monocrotaline (MCT) okuvela obala okulingisa okutholakele okujwayelekile 
kubantu. Umthelela wemithi yezidambisigciwane uyimpikiswano; noma kunjalo, i-nucleoside 
reverse transcriptase inhibitors (NRTI) ne-proteinase inhibitors (PI) ikhonjisiwe ukuthuthukisa 
umphumela kumamodeli wezilwane. Ucwaningo lwenziwe ukuze kuvivinywe ukuthi imishanguzo 
yegciwane lengculaza ingakhulisa i-MCT ingene kumodeli yama-rat futhi ikhombe ongaba 
ngumthengisi we-biomarker we-PH. 
 
Imvume yanikezwa yiKomidi Lezimilo Zokucwaninga Ngezilwane lesikhungo (AREC / 066 / 
018M) saseNyuvesi yaKwaZulu-Natali (UKZN), eThekwini, South Africa, ukuthi lenze izifundo. 
Amagundane angamashumi amane amaduna akwaSprague-Dawley (isisindo somzimba: 200-250 
g) ahlukaniswe ngezikhathi ngamaqembu amahlanu (n = 8 ngeqembu ngalinye). Amaqembu 
okwelashwa athole umjovo owodwa we-intraperitoneal we-MCT (60 mg Kg-1) ngenkathi iqembu 
elilawulayo lithola umthamo olinganayo womjovo we-saline we-intraperitoneal.  I-Zidovudine 
(100mg Kg-1), i-ritonavir (30mg. Kg-1), noma inhlanganisela yazo zombili lezi zidakamizwa (i- 
zidovudine 100mg. Kg-1 kanye ne-ritonavir 30mg. Kg-1) yayilawulwa nsuku zonke esikhathini 
sokufunda sezinsuku ezingama-28 kuya amagundane ngamaqembu amathathu kulawa amane ane- 
MCT izinsuku ezingama-28 ngokulandelana. Ngosuku lwamashumi amabili nesishiyagalombili 
locwaningo, kwenziwa imihlatshelo, kwahlolwa amasitho. Isisho se-Gene sisebenzisa i-RT-PCR 
yama-antioxidants, ASK-1 kanye ne-laby assay ye-lipid peroxidation kwahlaziywa. 
 
Inkulumo ephakeme kakhulu ye-mRNA gene ye-catalase, superoxide dismutase, kanye ne- 
glutathione peroxidase kumagundane aphathisiwe yabonwa ngokuqhathaniswa 
nokungalandelwanga. Kwakukhona ukwanda kwe-malondialdehyde (MDA) izicubu zenhliziyo 
zamagundwane angahlushwanga (37.01 ± 1.16nmol / g, p <0.0001) ngokuqhathaniswa neqembu 
lokulawula (3.46 ± 0.97 nmol / g) nokwehliswa okuhlobene kwe-MDA ngama-antiretrovirals . 
Ngaphezu kwalokho, ukukhuphuka kwenani eliphelele le-antioxidant umthamo (TAC) ku-AZT 
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(0.85 ± 0.02 nmol / g, p <0.0001), RTV (0.627 ± 0.03 nmol / g, p <0.0001) kanye nokuhlanganiswa 
kwe-AZT / RTV (0.765 ± 0.06 nmol / g, p <0.0001) ngokuqhathaniswa namagundane 
angaphendulwanga (0.28 ± 0.03). 
 
Ngaphezu kwalokho, ukuveza okungaphansi kwe-mRNA uhlobo lwe-ASK-1 enhliziyweni 
yamagundane aphathwe nge-zidovudine (2.67 ± 0.09, p <0.0001), ritonavir (2,57 ± 0.11, p <0.0001) 
kanye nenhlanganisela yomibili (2.75 ± 0.06, p. <0.0001) uma uyiqhathanisa namagundane eqenjini 
elingalwanga. Uhlobo lwe-mRNA olu-overexpressed lwe-ASK-1 kumagundane angalwanga (12.0 
± 0.90, p <0.0001) uma luqhathaniswa nolawulo. 
 
Lolu cwaningo lukhombisa ubufakazi bokuthi i-zidovudine ne-ritonavir ameliorate MCT-indised 
PH kumagundane ngokucindezela ukucindezela kwe-oxidative. Futhi, i-ASK-1 iyi-biomarker 
eyiqiniso yezimpawu zokulwa ne-apoptotic ze-PH. Ukuthola kwethu kuzothuthukisa uphenyo 
olusha ngendima yabanye ababekade bengabanikazi bezokwelapha ku-PH kanye nezinzuzo 
zokwelapha ezingaba khona zemithi yezidambisigciwane ekuvimbeleni i-PH. 
 
Amagama angukhiye: I-Pulmonary Hypertension, ingcindezi ye-Oxidative, Izinhlobo ze-oxygen 
ezisebenzayo, iMonocrotaline, ASK- 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 Background 
 
Pulmonary hypertension (PH) is a complex, progressive and life-threatening vasculopathy 
characterized by increased pulmonary vascular resistance and elevated pulmonary arterial 
pressure resulting in right ventricular hypertrophy and failure (Hoeper et al., 2013; Hadri et al., 
2013). 
In the 1960s, a sudden rise in PH cases was observed in some European countries which was 
attributed to the use of anorectic stimulant, aminorex for the treatment of obesity. This prompted 
the first World Symposium on PH (WSPH) in October 1973, which was organised by the World 
Health Organisation (WHO). Subsequently, the periodic symposia, for regular review of the 
classification, definitions and current research in PH with the view of improving the patients’ 
management outcome (Condon et al., 2019). 
Pulmonary hypertension is a major global health issue that interfaces both communicable and 
non-communicable diseases. Globally, left-sided heart failure is the leading cause of PH, 
probably affecting 5–10% of individuals aged 65 years or older. However, HIV infection, 
schistosomiasis, post-streptococcal rheumatic heart disease, and sickle cell disease, which are 
often endemic in sub-Saharan Africa, are frequent causes of PH, which are given less attention, 
in these countries (Hoeper et al., 2016). With the recent advancements in this field, and the 
development of new drugs, there has been increased survival and improved quality of life in 
individuals living with PH however, no therapy currently provides a cure (Studer and Gilkin, 
2014). 
Despite the progress in the subject, there is an obvious gap in the definition, understanding of the 
pathogenesis, treatment options, and late diagnosis. The adopted definition from the first WSPH 
in 1973, regarded PH as a mean pulmonary arterial pressure (mPAP) ⩾25 mmHg at rest, 
measured by right heart catheterisation which is the gold standard for diagnosis (Simonneau et 
al., 2019). In the definition of PH during exercise, an arbitrary figure of mPAP >30 mmHg was 
earlier used, but currently under review, as it is not supported by published data and healthy 
individuals were found to have much higher values than this predetermined value (Galie et al., 
2009). However, the latest review at the 6th WSPH, February 2018, the task force proposed to 
include pulmonary vascular resistance ⩾3 Wood units in the definition of all forms of pre- 
capillary PH associated with mPAP >20 mmHg but exercise PH was not considered by the task 
force for the lack of convincing data (Galie et al., 2019). 
Over the decades, preclinical/translational studies have played a major role in advancing the 
understanding of the pathogenesis and therapeutics in PH. Emphasis has been placed on one of 
the several pathogenetic mechanisms which underpins PH and these include, pulmonary 
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vasoconstriction, abnormal remodelling, and exaggerated perivascular infiltration of 
inflammatory cells. However, highlighting the role of vasoconstriction has been the rationale for 
the development of most currently available treatment modalities which focuses on vasodilation, 
with little or no attention on the therapeutic significance of the other pathogenetic mechanisms 




Pulmonary hypertension is a challenging health issue with an estimated global prevalence of one 
percent in the general population. It is widely distributed across the different age groups but the 
highest prevalence of about 10 percent is seen in the geriatric age group. Currently, there are 
limited information on the burden of PH in developing countries, however an estimated 80 
percent of the 75 million people who suffer from PH are domicile in the developing countries 
(Maarman et al., 2020). These are mostly low-middle income countries where the burden of PH 
related to infectious diseases is high and likewise experiencing the epidemiologic transition in 
the burden of non-communicable diseases similarly responsible for PH in such regions (Hoeper 
et al., 2016; Borges, 2017). 
The variation in the prevalence of PH has observed by the differences in the study methodologies 
and geographic distribution of PH. The discrepancy is further expressed in the non-uniformity in 
the definition, and assessment of PH especially in the utilization of RHC which is the standard 
for diagnosis. For instance, a Brazilian study reported schistosomiasis as a major of cause of PH 
due to the high burden of schistosomiasis and likewise in some regions in Africa like Egypt. This 
has been recognized by the WHO as a neglected and endemic cause of PH in developing countries 
(Piscoya Roncal et al., 2019; Farrag et al., 2012). On the contrary, the European and North 
American registries have reported connective tissue diseases as the most common cause of PH 
which is often due to scleroderma (Prins and Thenappan, 2016). 
A subgroup of PH is known as pulmonary arterial hypertension (PAH) is related to autoimmune 
diseases. The incidence of PH, in the developed world varies from 1·1–7·6 per million adults per 
year while the prevalence varies from 6·6–26·0 per million adult population respectively in the 
developed world (Hoeper et al., 2016). While the younger age groups are more likely to be 
affected by PH, and mostly seen in females, particularly in the heritable PAH affecting twice as 
many females as males before the age of 50 years. The global registry data on PH also supports 
this female preponderance (2–4 times) of PH over males (Örem, 2017). 
In experimental animal models, female animals are protected from the development of PH by the 
effects of oestrogen in a phenomenon known as the “oestrogen paradox” or “sexual dimorphism” 
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(Huber et al., 2015). This finding in animals suggest oestrogen to be strongly protective against 
the development of PH which is contrary to the high occurrence of PH in human subjects. 
Researchers have shown oestrogen and oestrogen receptor-based therapies to be necessary to 
ameliorate established pulmonary hypertension in animals but this role is yet to be defined in 
humans (Umar et al., 2012). 
Mutations in the bone morphogenetic protein receptor 2 gene (BMPR2) are associated with 
familial PH in about 70% of cases and could be sporadic in 11–40% of cases. While genetic 
predisposition accounts for only 1–5% of PH cases, autoimmune diseases and infections are also 
closely linked to PAH as possible triggers for the expression in those genetically predisposed 
(Batton et al., 2018). BMPR2 is a member of the transforming growth factor-beta (TGF-β) 
receptor superfamily which consist of mediators that regulate cellular functions, like 
differentiation, apoptosis, proliferation, migration, extracellular matrix secretion and deposition 
etc (Thenappan et al., 2018). 
The racial distribution of PH was explored in the Registry to Evaluate Early and Long-term PAH 
Disease Management (REVEAL) study, where the patient distribution was 72.8 %, 12.2 %, 8.9 
%, 3.3 % and 2.8 % in the Caucasians, African Americans, Hispanics, Asians or Pacific Islanders, 
and other or unknown groups respectively (Medrek and Sahay, 2018).Although the racial 
proportion was similar to the US population registry among the Caucasian group, there is a slight 
variation in the percentages in the other groups, as there was an overrepresentation of African 
Americans (12.2% vs. 10.9%) and underrepresentation of Hispanics (8.9% vs. 11.5%), and 
Asians/pacific islander (3.3% vs. 4.3%) in this study (Prins and Thenappan, 2016; Elliott et al., 
2019). 
Several of the risk factors for PH are hyperendemic in sub-Saharan Africa, among them are HIV 
infection, rheumatic heart disease, hereditary hemoglobinopathies, schistosomiasis, tuberculosis 
and chronic obstructive pulmonary diseases. Despite the recent global awareness on PH, the 
epidemiology in Africa still remains poorly described and yet to be given the deserved attention 
(Bigna et al., 2017). 
HIV/AIDS is characterized by a 2500‑fold increase risk of developing PH when compared to the 
general population and the survival of HIV associated PH (HIV-PH) patients is fifty percent 
(Zuber et al., 2004). In human subjects, HIV-PH has an average age at presentation of 33 years 
with slight female predominance (Bloomfield et al., 2014). This prevalence of HIV-PH has 
remained stable in the developed countries ranging from the initial 0.5% in the Swiss cohort 
survey of 1200 intravenous drug users who were HIV patients and 0.46% in a prospective cohort 
study of 7648 HIV-infected individuals in France (Barnett and Hsue, 2013). However, with the 
huge burden of HIV/AIDS in sub-Saharan Africa, where it constitutes about 70% of global HIV 
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burden, a critical review of this challenge in this region is necessary to establish the burden of 
HIV-PH. There are limited studies conducted in Africa on this subject, however, the prevalence 
of PH among HIV infected people in the available studies varies from 5 to 13 %, which is higher 
than the reported values in the developed countries (Cicalini et al., 2011; Janda et al., 2010). The 
reported higher prevalence of HIV-PH in Africa may be connected to the differences in the 
available diagnostic tools, as the majority of these prevalence studies were determined on the 






PH is a heterogenous group of diseases classified based on pathophysiology, clinical 
presentation, and therapeutic conditions into five categories, by the World Health Organisation, 
viz-a-viz PAH (group 1), PH due to left-sided heart disease (group 2), PH due to lung disease or 
hypoxia (group 3), chronic thromboembolic PH (CTEPH) and other pulmonary artery 
obstructions (group 4), and PH with unclear and/or multifactorial mechanisms (group 5) 
(Simonneau et al., 2019). 
Group 1 PH consists of idiopathic, heritable, drug and toxin-induced, HIV associated and 
connective tissue disease, portal hypertension, and schistosomiasis. In this group, the hereditary 
PAH and idiopathic PAH are also described, which are linked to mutation in genes like the bone 
morphogenetic protein receptor 2 gene (BMPR2). This group is selectively known as the PAH, 
as all have same characteristics features on histology. Most the available therapeutic options are 
focused on PAH which remains treatable disease but still has high mortality (Condon et al., 2019) 
Group 2 PH is attributed to left-sided heart disease, comprising heart failure with reduced ejection 
fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), as well as mitral or 
aortic valve disease, or congenital/acquired left inflow or outflow tract obstruction and congenital 
cardiomyopathies (Goldberg et al., 2017). 
Group 3 PH is caused by chronic lung disease and/or hypoxia. It is most commonly associated 
with chronic obstructive pulmonary disease (COPD), parenchymal lung disease and sleep- 
disordered breathing (Heresi et al., 2017). 
Group 4 is classified as CTEPH, which often results from abnormal clotting cascade, 
dysfunctional endothelial cells or platelets with organised fibrotic material resulting in the clot 
formation within the pulmonary vasculature either as residual pulmonary thromboembolism 
(PTE) or in situ thrombosis causing mechanical obstruction of pulmonary arteries (Hughes et al., 
2006). 
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Group 5 refers to PH with unclear and/or multifactorial mechanisms. This group has represented 
less-studied forms of PH, with likely multiple pathophysiological phenomena involved in this 
process, however, many of the PH forms currently in group 5 represent a significant part of the 
yet unrecognised worldwide burden of PH (Simonneau et al., 2019). 
 






The pathogenesis of PH is complex and multifactorial, characterised by the triad of excessive 
vasoconstriction, microthrombosis and remodelling of pulmonary arteries. Despite the 
vasoconstrictive process being the most studied while the remodelling is arguably the most 
important factor, there are complex entities in the pathogenesis that is still poorly understood 
(Huber et al., 2015). A heterogenous process of endothelial vascular injury results in a chaotic 
endothelial proliferation and haphazard endothelial cellular migration to all pulmonary arteriolar 
layers (Humbert et al., 2004). This vascular remodelling of pulmonary arteries which 
encompasses concentric medial thickening of small arterioles, neomuscularization of previously 
non-muscular capillary-like vessels, and structural wall thickness in larger pulmonary arteries is 
characterized by vascular smooth muscle cell (SMC) hyperplasia and hypertrophy (Aggarwal et 
al., 2013). 
The most emphasized of the several proposed mechanisms for the observed pathogenesis of PH 
is the vasoconstrictive changes which is hinged on three processes that prevent pulmonary 
vasodilation. The three key signalling pathways outlined affect nitric oxide (NO), prostacyclin 
(PGI2) and endothelin-1 (ET-1) (Lan et al., 2018). There is a decrease in the bioavailability of 
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NO from an enzymatic uncoupling of endothelial nitric oxide synthase (eNOS) resulting in the 
reduction in NO synthesis. This manifests as pulmonary vasoconstriction and increased smooth 
muscle cell proliferation, inflammation and thrombosis (Alp and Channon, 2004). Likewise, in 
the prostacyclin (PGI2) pathway, PGI2 produced by the endothelial cells binds to specific receptor 
known as the I-prostanoid (IP) receptors in the vascular smooth muscle cells which activates 
smooth muscle relaxation and vasodilation by cyclic AMP generation from ATP. In addition, 
PGI2 prevents platelet aggregation and smooth muscle proliferation. This receptor blockage has 
been demonstrated in IP-knockout mice with subsequent vascular remodelling with exposure to 
chronic hypoxia resulting in severe PH and also demonstrated in humans (Hoshikawa et al., 
2001). In the endothelin-1 (ET-1) pathway, ET-1 which is a potent vasoconstrictor acts on ETA 
and ETB receptors and the resultant PH. An increased plasma and pulmonary vascular endothelial 
concentrations of ET-1 in cells is responsible for the vasoconstriction (Giaid et al., 1993). 
 
 
Figure 2: Adapted from the key abnormal pathways targeted in the pharmacological treatment of 
PH and the mechanism of action for contemporary drugs. (Lan et al., 2018) 
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With the remodelling, there is an imbalance in the pro-proliferative and apoptotic cellular 
activities within the vessels, which is triggered by BMPR2. Therefore, the mutation in BMPR2 
on chromosome 2q33 alters the cellular processes and determine the developmental fate during 
embryogenesis. This predisposes the mutant carrier to develop PH in the presence of a favourable 
exogenous stimuli (Said, 2006). 
In addition, inflammation is an emerging concept in the pathogenesis of PH. Several 
inflammatory cells are shown to infiltrate the pulmonary vasculature in response to infectious 
agents and injurious endothelial damage (Huber et al., 2015). This has been demonstrated in 
humans and animal models where inflammatory cells including lymphocytes, macrophages, 
dendritic cells and mast cells invade the pulmonary vasculature. Similarly, infectious diseases 
and related diseases like HIV/AIDS, systemic sclerosis and systemic lupus erythematosus have 
exhibited qualitative and quantitative abnormalities in their T-regulatory cells. Despite this 
available body of knowledge, researchers are yet to fully explore drugs with anti-inflammatory 
properties or design medications to specifically target inflammatory processes (Hemnes and 
Humbert, 2017). This might have played a significant role in the steady prevalence of HIV-PH 
as antiretroviral medications have demonstrated effects on viral antigens in vascular changes 
among HIV patients (Szturmowicz et al., 2015). In rat model of PH, increased IL-6 has been 
associated with the development of PH which was reversed by an early administration of anti- 
inflammatory drugs (dexamethasone) as well as attenuation of the PH developmental process 
(Bhargava et al., 1999). In addition, monitoring of the inflammatory process, using an acute phase 
reactant like C-reactive protein (CRP) has been reported as a predictor of outcome and response 
to therapy in PH. Further evidence suggests that this inflammatory mechanism could potentially 
be the target for management of remodelling in PH (Sydykov et al., 2018). 
Furthermore, enhanced production and dysregulated ROS/RNS signalling has been implicated in 
the pathogenesis of PH. This is evident by the elevation in the ROS and direct mop-up of NO by 
superoxide resulting in a disequilibrium in ROS/RNS. This further encourages pro- proliferation, 
pro-survival phenotypes and DNA damage in the pulmonary vascular (Jernigan et al., 2004; 
Ranchoux et al., 2016). Gratton et al found that the administration of a protease inhibitor 
(antiretroviral medications) in a cell line, significantly increased tROS production, and apoptosis 
(Gratton et al., 2018). Furthermore, ROS causes contraction of pulmonary vessels which is 
mediated by hypoxia, and the release of RNS from the endothelium of blood vessels (Fulton et 
al., 2017). 
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1.2 Animal models of pulmonary hypertension 
 
Animal models were developed to study the functional and structural changes in PH due to the 
limited human tissue samples. However, no single preclinical model is a flawless replica of the 
PH presentation in humans. In the bid to unravel this fatal condition, researchers have employed 
experimental animal models to execute mechanistic studies, and evaluate potential therapeutic 
options (Huetsch et al., 2016). 
The most extensively used animal models of PH have been chronic hypoxia and the MCT- 
induced PH rodent models (Nogueira-Ferreira et al., 2015). These models have complemented 
the understanding of the mechanisms of pulmonary vascular remodelling in PH but are limited 
by the lack of the typical complex vascular neointimal lesions and severe disease phenotype seen 
in PAH (Dickinson et al., 2013). Although, widely used, it has been characterized predominantly 
by media hypertrophy of the pulmonary vessels but lack the vaso-occlusive and plexiform lesions 
that are the hallmark of severe human PAH (Lahm et al., 2014). Few animal studies are available 
in the literature regarding the other categories of PH aside PAH that is widely studied (Breitling 
et al., 2015). 
 
 
1.2.1 Monocrotaline-induced pulmonary hypertension 
 
In the discovery by J. M. Kay and his colleagues, powdered Crotolaria spectabilis seeds induced 
PH in rats due to an alkaloid monocrotaline (MCT) (Scupinari et al., 2020; Kay et al., 1967). 
Mice do not develop PH from MCT due to the deficiency of CYP3A isoenzyme in the mouse 
liver, required to metabolize MCT to its active metabolite. MCT is an 11-membered macrocyclic 
pyrrolizidine alkaloid derivative of the Crotalaria spectabilis from the seeds of the plant. It is 
activated to the reactive pyrrole metabolite dehydromonocrotaline (MCTP) in the liver, a reaction 
that is highly dependent on cytochrome P-450 (CYP3A4) (Gomez-Arroyo et al., 2012). The 
application of MCT model of PAH has been in existence in the last five decades. This is induced 
by a single dose injection of either intraperitoneal or subcutaneous administration of MCT into 
the rat. Following its administration, the circulating MCTP has high affinity for the pulmonary 
arterial endothelial lining and leads to irreversible cell injury, vascular inflammation, and 
remodelling (Feng et al., 2017; Barman et al., 2009). In the first two weeks following MCT 
administration, usually no overt physical disorder may be noticed, however, after three weeks, 
the animal begins to deteriorate from progressive thickening of the media and muscularization 
of non-muscularized arteries, along with adventitial proliferation (Santos-Ribeiro et al., 2016). 
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The mechanisms underlying this progression remain poorly understood, although there has been 
established endothelial damage following MCT administration. Several researchers have 
postulated possible explanations like the development megalocytosis by the pulmonary arterial 
endothelial cells (PAEC), disruptions of intracellular membrane trafficking that affect several 
cell membrane proteins and the deregulation of nitric oxide signalling, leading to lung vascular 
changes (Gomez-Arroyo et al., 2012). In addition, MCT also causes hepatic veno-occlusive 
disease in rats as well as biventricular myocarditis resulting in right ventricular hypertrophy and 
failure (Sztuka and Jasinska-Stroschein, 2017). 
 
1.2.2 Global Burden of HIV/AIDS 
 
HIV epidemic is a major global health issue. According the WHO, since the onset of this 
epidemic, over 70 million people have been infected with HIV and close to 35 million people 
have died as a result of HIV/AIDS. In 2018, approximately 37.9 million people were living with 
HIV, 1.7 million newly infected people with HIV, 770 000 people have died from AIDS-related 
illnesses, with about 23.3 million accessing antiretroviral therapy. To further reduce the 
prevalence of HIV/AIDS, the Joint United Nations Programme on HIV and AIDS (UNAIDS) set 
a target known as the 90-90-90 in the year 2014 that 90% of all HIV positive people will be 
diagnosed, 90% of all those diagnosed will be on treatment and 90% of those on treatment will 
be virally suppressed (Jones et al., 2019; UNAIDS, 2019). The transmission of HIV infection is 
through several routes like sexual contact, blood transfusions, mother-to-child transmission, 
intravenous drug use and needle-stick injuries (Jones et al., 2019). Ever since the first case of 
HIV associated PH was identified in 1987, it has become a well-recognized complication of HIV 
infection and increased morbidity (Barnett and Hsue, 2013). 
 
1.2.3 Burden of HIV/AIDS in Africa 
 
HIV/AIDS is a major cause of morbidity and mortality in sub-Saharan Africa. This region 
represents about 12% of the global population yet it harbours 71% of the global burden of HIV 
infection. Since HIV was first recognized in the 1980s, notable scientific breakthroughs have 
changed the once fatal condition into manageable one, with the introduction of anti-retroviral 
therapy (ART). Despite the discovery of ART since the mid-2000s and the resulting decline in 
mortality, 34% of people in east and southern Africa and 60% of people in west and central 
Africa living with HIV are currently not receiving any treatment (Colombe et al., 2018; Bain and 
Gwain, 2019). Sub-Saharan African countries lag behind in HIV treatment cascade, with 
significant pressure on the limited health care facilities and the concomitant rise in the burden of 
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non-communicable disease (NCD) which has great implications for ART programmes (Smit et 
al., 2018). With the enormous disease burden in Africa, Southern Africa is still the most severely 
affected region in the continent with an estimate of about 11.3 million people living with HIV 
and AIDS. In 2013, it was estimated that 10% of the total population of South Africa was HIV 
positive (Mohapi and Pitsoane, 2017). 
 
 
1.2.4 Pathogenesis of HIV-induced PH 
 
Following the transmission of the virus, the viral entry into the human cells is facilitated by the 
CD4 receptors: C-C chemokine receptor-5 (CCR5) and C-X-C chemokine receptor-4 (CXCR4). 
These viruses may hibernate in cells by downregulating the key host receptors and evading the 
host immune surveillance or commence active replication and reinfection of other cells. There 
are nine genes that encode HIV-I proteins with three of these genes (gag, pol, and env) found in 
all retroviruses. While the gag and pol regions encode for the reverse transcriptase and integrase 
enzymes, the env gene encodes for gp160 which is the precursor for the envelope proteins gp120 
and gp41 necessary for the viral cell entry (Porter and Sutliff, 2012). 
Although HIV has not been detected in the pulmonary vasculature lesions of patients but the viral 
proteins are strongly linked to have a cause-effect relationships by promoting apoptosis, growth, 
and proliferation in the pulmonary vasculature (Almodovar et al., 2010) Several studies have 
implicated HIV proteins like trans-activator of transcription (Tat), glycoprotein (gp) 120, 
negative regulator factor (nef) and envelope protein (env) in the development of HIV-PH. 
However, the occurrence of HIV-PH has no correlation in several studies with the viral load, 
CD4 count or co-existing opportunistic infections in HIV patients (Almodovar et al., 2011; 
Henriques-Forsythe et al., 2015). 
The role of chemokines and chemokine receptors in PH progression has been elucidated where 
significant upregulation of the CCR5 receptor was found in PH patients (Amsellem et al., 2014). 
HIV-Nef, downregulates the CD4 receptor, which stimulates viral replication in primary T-cells. 
HIV envelope gp-120, which is essential for viral attachment and fusion to the host cellular 
membrane, also it induces apoptosis and increases the secretion of endothelin-1 from human lung 
endothelial cells (Barnett and Hsue, 2013). Similarly, HIV env stimulates monocytes and 
macrophages to release proinflammatory cytokines, while the HIV Tat protein activates 
endothelial cells and has angiogenic properties. (Almodovar et al., 2010). 
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1.2.4.1 Pharmacology of antiretroviral drugs 
 
HIV is a retrovirus which causes AIDS. It was co-discovered by Barre-Sinoussi et al. and Gallo 
et al. about four decades ago and has two strains which are HIV-1 and HIV-2. The HIV-1 strain 
is widespread but predominant in America, Europe and Asia while HIV-2 represents a significant 
minority of HIV infections, mostly in West Africa countries, which is less readily transmitted 
and less pathogenic than HIV-1 (Almodovar, 2014). 
HIV produces more than 10 billion virions per day, which is a rapid viral turnover (new 
generation every 2.6 days) (Almodovar, 2014). The different classes of antiretroviral drugs act 
by preventing viral replication and thereby reduce the viral load to undetectable level in the blood. 
In 1986, the first antiretroviral drug zidovudine (ZDV) was introduced, and other antiretroviral 
drugs followed. There are currently 26 drugs divided into 6 classes based on their mechanisms 
of action. The combination of ART in the different groups was adopted to address the 
development of drug resistance, hence currently three or more ARVs are recommended 
worldwide for the treatment of people with HIV infection (Arts and Hazuda, 2012). 
 
 
Figure 3: Adapted from HIV-1 life cycle and current targets for antiretroviral therapy (Sierra- 
Aragon and Walter, 2012). 
 
The first approved class of ARVs was the nucleotide reverse transcriptase inhibitors (NRTIs), 
which when administered, requires the host cell entry and phosphorylation by cellular kinases 
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for effective antiviral action. NRTIs lack 30-hydroxyl group at the sugar (20-deoxyribosyl) 
moiety and requires bonding of the 50-nucleoside triphosphates for the formation of a 30-50- 
phosphodiester bond for the termination of the growing viral DNA chain. The approved drugs in 
this category are abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, 
zidovudine, and Tenofovir disoprovil fumarate (Barroso et al., 2019). 
The prototype in the NRTI group is zidovudine. It is a thymidine analogue that inhibits the 
mitochondrial adenylate kinase and adenosine nucleotide translocator in isolated mitochondria 
and diminishes oxidative phosphorylation. It causes haematological complications like bone 
marrow suppression (pancytopenia), malaise, anorexia, nausea, vomiting, lactic acidosis, and 
loss of limb fat (Rai et al., 2018). 
Non-nucleotide reverse transcriptase inhibitors (NNRTIs) are non-competitive inhibitors of 
reverse transcriptase enzyme. They alter the conformation of the substrate-binding site and 
reduce polymerase activity after binding with an allosteric non-bonding site of the viral reverse 
transcriptase. This group is highly specific for the HIV-1 reverse transcriptase (RT), as they do 
not inhibit the HIV-2. The approved NNRTIs are etravirine, delavirdine, efavirenz, nevirapine, 
and rilpivirine however delavirdine is no longer used as a component of ART treatments 
(Famiglini and Silvestri, 2016). 
Protease inhibitors (PIs) prevent the cleavage of the viral gag and gag-pol polyprotein precursors 
during virion maturation. Due to their interaction with GLUT1 and GLUT4 glucose transporters, 
insulin resistance and hyperglycemia could occur. Approved PIs are amprenavir, atazanavir, 
darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir 
(Arts and Hazuda, 2012; Barroso et al., 2019). 
Fusion inhibitors bind to gp41 on the viral envelope and prevent peptide fusion inhibitors 
required for the two homologous domains in the viral gp41 protein interaction. The available 
drug in this category is enfuvirtide, with local reactions at the injection site being the most 
common adverse effect. (Barroso et al., 2019). 
CCR5 chemokine antagonists bind to hydrophobic pockets within the transmembrane helices of 
CCR5 and prevent the binding by HIV-1 envelope. CCR5 is a G-protein coupled chemokine 
receptors determining HIV-1 cellular tropism. The viruses preferentially utilize CCR5 (R5 
strains) co-receptor mainly expressed on macrophages for entry into the host cell. Lack of CCR5 
receptors in certain individuals make them resistant to HIV. The approved drugs in this category 
are maraviroc, vicriviroc and aplaviroc (Abrol et al., 2014; Tilton et al., 2010). 
Integrase strand transfer inhibitors (InSTIs) prevent HIV replication by inhibiting the integration 
of HIV DNA to human genome. InSTIs have fewer adverse effects than other classes of 
antiretroviral agents. They target the strand transfer reaction and interact with two essential 
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elements of the virus, the integrase enzyme as well as the viral DNA, which is the substrate for 
integration. Approved drugs are raltegravir, elvitegravir, dolutegravir (Chen et al., 2019). 
 
1.2.4.2 Effects of antiretroviral drugs in PH 
 
There is ambiguity in the literature on the role of ART in HIV-PH, while some reports suggest 
that ART has no effect on the presence or severity of PH, the French cohort showed that ART 
improved exercise tolerance and physical performance in PH patients (Humbert et al., 2006) . In 
animal models, protease inhibitors have been shown to significantly reverse hypoxia-induced PH 
(Barnett and Hsue, 2013; Degano et al., 2009). 
Chronic inflammation is considered as an important component of PH that contributes to the 
structural pulmonary-vessel remodelling (Amsellem et al., 2014). Hence, corticosteroids and 
immunosuppressive therapy were found to reduce the manifestations in severe PH which further 
emphasizes the critical role of inflammation in this condition (Morris et al., 2012). 
Some studies have reported the efficacy of ART in decreasing morbidity and mortality in patients 
with HIV-PH (Jarrett and Barnett, 2017). On the contrary, a retrospective study found a higher 
risk of PH in patients treated with protease inhibitor compared to patients treated with nucleoside 
reverse transcriptase inhibitors (Dhadwal et al., 2009). This finding may be due to the fact that 
protease inhibitors (PI) have been associated with several cardiovascular risk factors like 
hyperlipidemia, lipodystrophy and insulin resistance which correlation with endothelial 
dysfunction (Stein et al., 2001). However, in an animal model, first generation PIs partially 
prevented the development of hypoxia and monocrotaline-induced PH. PIs inhibit aspartyl 
protease required for HIV viral replication. The growth-inhibiting and insulin-resistance- 
inducing effects of PIs ameliorate pulmonary artery smooth muscle proliferation which supports 
the pulmonary vascular remodelling as a possible mechanism for the PH (Gary-Bobo et al., 
2010). There is a gap in the literature on the effects of oxidative stress in the development of PH 
following the administration of ARVs. 
 
 
1.2.4.3 Novel Biomarkers 
 
PH is a multifactorial and heterogeneous disorder with varying aetiopathogenesis. Therefore, the 
search for minimally invasive, high specificity and sensitivity, biomarkers for the purpose of 
diagnosis, prognosis, and treatment response would be ideal in the management of PH. However, 
currently, there are no known available single marker for accurate diagnosis or monitoring of 
disease progression in PH (Huetsch et al., 2016). 
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1.2.4.4 B-Type natriuretic peptide (BNP) 
 
BNP was first isolated from the porcine brain in 1988, but it was later found to originate from 
the ventricular myocardium. The synthesized and secreted BNP is a prehormone of 108 amino 
acid which cleaves to the active 32 amino acid BNP and its inactive 76 amino acid N-terminal 
fragment (Weber and Hamm, 2006).The release of this hormone is usually triggered by 
myocardial wall stress, ischemia or infarction resulting in heart failure (Omland et al., 2007). 
BNP is stable at room temperature in whole blood with the addition of EDTA as anticoagulant 
for at least 24 hours, whereas NT‐proBNP is stable for at least 72 hours. However, both BNP and 
NT-proBNP are stable during freezing and thaw processes (Weber and Hamm, 2006). 
The usefulness of BNP has been demonstrated in right ventricular dysfunction, prediction of 
elevated pulmonary artery pressure and prognostication of outcome of the PH (Goto et al., 2010). 
Its role as a potent pulmonary vasodilator and anti-hypertrophic agent has been explored in the 
inhibition of pulmonary vascular remodelling following maladaptive changes in the ventricular 
myocardium (Casserly and Klinger, 2009). Leuchte et al demonstrated the association between 
this non-invasive blood test and pulmonary hemodynamics as well as the negative correlation 
with 6 minutes exercise test in human subjects. BNP remains the most widely used biomarker in 




1.2.4.5 Apoptosis signal-regulating kinase-1 (ASK-1) 
 
ASK-1 is a signal pathway activated in response to oxidative stress that stimulate apoptosis, 
inflammation, and fibrosis within pulmonary vascular and right ventricular remodelling in PH. 
Its inhibition prevents pathological vascular remodelling and terminates the progression of PH 
in a rat model (Budas et al., 2018). Furthermore, the regulation of ASK-1 has been linked to 
cardiac hypertrophy, cardiac remodelling, atherosclerosis and systemic hypertension (Liu et al., 
2017). ASK-1 is also required for the execution of reactive oxygen species (ROS)-induced 
apoptosis essentially through mitochondria-dependent caspase activation. Hayakawa et al. 
reported the protective role of ASK-1 in HIV infection through its downregulation following its 
interaction with the viral nef protein which enables apoptosis of surrounding T-cells (Hayakawa 
et al., 2012). 
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1.2.4.6 Reactive Oxygen Species 
 
ROS play a significant role in vascular dysfunction which accounts for PH (Adesina et al., 2015). 
ROS are naturally formed free radicals which are by-products of oxygen metabolism. They 
include hydroxyl, superoxide, peroxyl and non-radical species, such as hydrogen peroxide. Due 
to their unpaired and highly reactive outer shell, they react with the vascular endothelial causing 
oxidative damage to the cells (Aggarwal et al., 2013). The resultant uncontrolled proliferation 
and impaired apoptosis of pulmonary artery smooth muscle cells (PASMC) contributes to 
vascular obstruction and ultimately pulmonary hypertension (Archer et al., 2010). 
 
 
1.2.4.7 Inflammatory biomarkers 
 
Animal models of PH and humans have varying extent of perivascular inflammatory cells, which 
include T- and B-lymphocytes, dendritic cells (DCs), mast cells and macrophages (Rabinovitch 
et al., 2014). Identification of a suitable biomarker can serve as a less invasive tool for diagnosis, 
monitoring, prognosticating, and assessment of response to treatment. Several inflammatory 
mediators, including IL-1α, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, IL-12p70, TNF-α, and 
CRP are upregulated in PH but none is documented to be specific for this purpose (Sydykov et 
al., 2018). 
 
1.3 Future research 
 
1.3.1 Cancer research 
 
An investigation into the major similarities between PH and cancer cells, could improve the 
knowledge on PH and further help in oncology, especially in the explanation of the possible 
mechanisms in the prevention of tissue invasion and metastasis (Guignabert et al., 2013). 
Specifically, the pro-proliferative and antiapoptotic characteristics of PH which is typical of the 
manifestations in cancers (Cottrill and Chan, 2013). A common phenomenon in both conditions, 
Warburg metabolism, is a failure of two fundamental pathways glucose metabolism and 
mitochondrial oxygen sensing (Archer, 2017). A possible biomarker which could also be 
explored is survivin, an apoptosis protein inhibitor, often expressed in cancerous tissue and also 
demonstrated in pulmonary vascular remodelling in rats developing monocrotaline-induced PH 




This study will test the hypothesis that ARVs administration ameliorates monocrotaline-induced 
PH in rat model. 
 
1.5 Aims of the study 
i. To understand the effect of ARVs on the progression of MCT-induced PH in rats. 
ii. To investigate the protective effect of ARVs in the development of MCT-induced PH 
in a rat model. 
1.6 Objectives of the study 
i. To investigate the histopathological features in the pulmonary vasculature, right heart 
thickness and perivascular changes in the lungs. 
ii. To investigate the involvement of ASK-1 in pulmonary vascular and right ventricular 
remodelling. 




Abrol R, Trzaskowski B, Goddard WA, 3rd, et al. (2014) Ligand- and mutation-induced 
conformational selection in the CCR5 chemokine G protein-coupled receptor. Proc Natl 
Acad Sci U S A 111: 13040-13045. 
Adesina SE, Kang BY, Bijli KM, et al. (2015) Targeting mitochondrial reactive oxygen species 
to modulate hypoxia-induced pulmonary hypertension. Free Radic Biol Med 87: 36-47. 
Adnot S. (2005) Lessons learned from cancer may help in the treatment of pulmonary 
hypertension. J Clin Invest 115: 1461-1463. 
Aggarwal S, Gross CM, Sharma S, et al. (2013) Reactive oxygen species in pulmonary 
vascular remodeling. Compr Physiol 3: 1011-1034. 
Almodovar S. (2014) The complexity of HIV persistence and pathogenesis in the lung under 
antiretroviral therapy: challenges beyond AIDS. Viral Immunol 27: 186-199. 
Almodovar S, Cicalini S, Petrosillo N, et al. (2010) Pulmonary hypertension associated with 
HIV infection: pulmonary vascular disease: the global perspective. Chest 137: 6s-12s. 
Almodovar S, Hsue PY, Morelli J, et al. (2011) Pathogenesis of HIV-associated pulmonary 
hypertension: potential role of HIV-1 Nef. Proc Am Thorac Soc 8: 308-312. 
Alp NJ and Channon KM. (2004) Regulation of endothelial nitric oxide synthase by 
tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 24: 413-420. 
Amsellem V, Lipskaia L, Abid S, et al. (2014) CCR5 as a treatment target in pulmonary arterial 
hypertension. Circulation 130: 880-891. 
Archer SL. (2017) Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial 
Hypertension: Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary 
Arterial Hypertension. Circulation 136: 2486-2490. 
Archer SL, Marsboom G, Kim GH, et al. (2010) Epigenetic attenuation of mitochondrial 
superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell 
proliferation and a new therapeutic target. Circulation 121: 2661-2671. 
Arts EJ and Hazuda DJ. (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect 
Med 2: a007161. 
17  
Bain LE and Gwain GC. (2019) Cardiovascular Disease and HIV Infection in Sub-Saharan 
Africa: Misplaced Priorities in the Public Health and Research Agendas? Front 
Cardiovasc Med 6: 35. 
Barman SA, Zhu S and White RE. (2009) RhoA/Rho-kinase signaling: a therapeutic target in 
pulmonary hypertension. Vasc Health Risk Manag 5: 663-671. 
Barnett CF and Hsue PY. (2013) Human immunodeficiency virus-associated pulmonary 
arterial hypertension. Clin Chest Med 34: 283-292. 
Barroso S, Moren C, Gonzalez-Segura A, et al. (2019) Metabolic, mitochondrial, renal and 
hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized 
crossover clinical trial in healthy volunteers. PLoS One 14: e0216712. 
Batton KA, Austin CO, Bruno KA, et al. (2018) Sex differences in pulmonary arterial 
hypertension: role of infection and autoimmunity in the pathogenesis of disease. Biol 
Sex Differ 9: 15. 
Bhargava A, Kumar A, Yuan N, et al. (1999) Monocrotaline induces interleukin-6 mRNA 
expression in rat lungs. Heart Dis 1: 126-132. 
Bigna JJ, Noubiap JJ, Nansseu JR, et al. (2017) Prevalence and etiologies of pulmonary 
hypertension in Africa: a systematic review and meta-analysis. BMC Pulm Med 17: 
183. 
Bloomfield GS, Khazanie P, Morris A, et al. (2014) HIV and noncommunicable cardiovascular 
and pulmonary diseases in low- and middle-income countries in the ART era: what we 
know and best directions for future research. J Acquir Immune Defic Syndr 67 Suppl 1: 
S40-53. 
Borges GM. (2017) Health transition in Brazil: regional variations and divergence/convergence 
in mortality. Cad Saude Publica 33: e00080316. 
Breitling S, Ravindran K, Goldenberg NM, et al. (2015) The pathophysiology of pulmonary 
hypertension in left heart disease. Am J Physiol Lung Cell Mol Physiol 309: L924-941. 
Budas GR, Boehm M, Kojonazarov B, et al. (2018) ASK1 Inhibition Halts Disease Progression 
in Preclinical Models of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 
197: 373-385. 
Casserly B and Klinger JR. (2009) Brain natriuretic peptide in pulmonary arterial hypertension: 
biomarker and potential therapeutic agent. Drug Des Devel Ther 3: 269-287. 
Chen GJ, Sun HY, Cheng A, et al. (2019) Risk of elevation of serum creatine kinase among 
HIV-positive individuals receiving dolutegravir-based combination antiretroviral 
therapy. Medicine (Baltimore) 98: e16235. 
Cicalini S, Almodovar S, Grilli E, et al. (2011) Pulmonary hypertension and human 
immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. 
Clin Microbiol Infect 17: 25-33. 
Colombe S, Machemba R, Mtenga B, et al. (2018) Impact of schistosome infection on long- 
term HIV/AIDS outcomes. PLoS Negl Trop Dis 12: e0006613. 
Condon DF, Nickel NP, Anderson R, et al. (2019) The 6th World Symposium on Pulmonary 
Hypertension: what's old is new. F1000Res 8. 
Cottrill KA and Chan SY. (2013) Metabolic dysfunction in pulmonary hypertension: the 
expanding relevance of the Warburg effect. Eur J Clin Invest 43: 855-865. 
Degano B, Yaici A, Le Pavec J, et al. (2009) Long-term effects of bosentan in patients with 
HIV-associated pulmonary arterial hypertension. Eur Respir J 33: 92-98. 
Dhadwal AK, Wang X, Annambhotla S, et al. (2009) Capsaicin blocks HIV protease inhibitor 
ritonavir-induced vascular dysfunction in porcine pulmonary arteries. Med Sci Monit 
15: Br1-5. 
Dickinson MG, Bartelds B, Borgdorff MA, et al. (2013) The role of disturbed blood flow in the 
development of pulmonary arterial hypertension: lessons from preclinical animal 
models. Am J Physiol Lung Cell Mol Physiol 305: L1-14. 
18  
Elliott CG, Austin ED, Badesch D, et al. (2019) United States Pulmonary Hypertension 
Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulm Circ 9: 
2045894019851696. 
Famiglini V and Silvestri R. (2016) Focus on Chirality of HIV-1 Non-Nucleoside Reverse 
Transcriptase Inhibitors. Molecules 21. 
Farrag A, El-Aroussy W, Zaghloul S, et al. (2012) Prevalence and severity of pulmonary 
hypertension in asymptomatic rural residents with schistosomal infection in the Nile 
Delta. Trop Med Int Health 17: 112-118. 
Feng S, Chen S, Yu W, et al. (2017) H2S inhibits pulmonary arterial endothelial cell 
inflammation in rats with monocrotaline-induced pulmonary hypertension. Lab Invest 
97: 268-278. 
Fulton DJR, Li X, Bordan Z, et al. (2017) Reactive Oxygen and Nitrogen Species in the 
Development of Pulmonary Hypertension. Antioxidants (Basel) 6. 
Galie N, Hoeper MM, Humbert M, et al. (2009) Guidelines for the diagnosis and treatment of 
pulmonary hypertension. Eur Respir J 34: 1219-1263. 
Galie N, McLaughlin VV, Rubin LJ, et al. (2019) An overview of the 6th World Symposium 
on Pulmonary Hypertension. Eur Respir J 53. 
Gamen E, Seeger W and Pullamsetti SS. (2016) The emerging role of epigenetics in pulmonary 
hypertension. Eur Respir J 48: 903-917. 
Gary-Bobo G, Houssaini A, Amsellem V, et al. (2010) Effects of HIV protease inhibitors on 
progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. 
Circulation 122: 1937-1947. 
Giaid A, Yanagisawa M, Langleben D, et al. (1993) Expression of endothelin-1 in the lungs of 
patients with pulmonary hypertension. N Engl J Med 328: 1732-1739. 
Goldberg AB, Mazur W and Kalra DK. (2017) Pulmonary hypertension: diagnosis, imaging 
techniques, and novel therapies. Cardiovasc Diagn Ther 7: 405-417. 
Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. (2012) The monocrotaline model of 
pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 302: 
L363-369. 
Goto K, Arai M, Watanabe A, et al. (2010) Utility of echocardiography versus BNP level for 
the prediction of pulmonary arterial pressure in patients with pulmonary arterial 
hypertension. Int Heart J 51: 343-347. 
Gratton R, Tricarico PM, Guimaraes RL, et al. (2018) Lopinavir/Ritonavir Treatment Induces 
Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG 
Cell Line. Curr HIV Res 16: 106-112. 
Guignabert C, Tu L, Le Hiress M, et al. (2013) Pathogenesis of pulmonary arterial 
hypertension: lessons from cancer. Eur Respir Rev 22: 543-551. 
Hadri L, Kratlian RG, Benard L, et al. (2013) Therapeutic efficacy of AAV1.SERCA2a in 
monocrotaline-induced pulmonary arterial hypertension. Circulation 128: 512-523. 
Hayakawa R, Hayakawa T, Takeda K, et al. (2012) Therapeutic targets in the ASK1-dependent 
stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci 88: 434-453. 
Hemnes AR and Humbert M. (2017) Pathobiology of pulmonary arterial hypertension: 
understanding the roads less travelled. Eur Respir Rev 26. 
Henriques-Forsythe M, Annangi S and Farber HW. (2015) Prevalence and hospital discharge 
status of human immunodeficiency virus-associated pulmonary arterial hypertension in 
the United States. Pulm Circ 5: 506-512. 
Heresi GA, Platt DM, Wang W, et al. (2017) Healthcare burden of pulmonary hypertension 
owing to lung disease and/or hypoxia. BMC Pulm Med 17: 58. 
Hoeper MM, Bogaard HJ, Condliffe R, et al. (2013) Definitions and diagnosis of pulmonary 
hypertension. J Am Coll Cardiol 62: D42-50. 
Hoeper MM, Humbert M, Souza R, et al. (2016) A global view of pulmonary hypertension. 
Lancet Respir Med 4: 306-322. 
19  
Hoshikawa Y, Voelkel NF, Gesell TL, et al. (2001) Prostacyclin receptor-dependent 
modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314- 
318. 
Huber LC, Bye H and Brock M. (2015) The pathogenesis of pulmonary hypertension--an 
update. Swiss Med Wkly 145: w14202. 
Huetsch JC, Suresh K, Bernier M, et al. (2016) Update on novel targets and potential treatment 
avenues in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 311: L811- 
l831. 
Hughes RJ, Jais X, Bonderman D, et al. (2006) The efficacy of bosentan in inoperable chronic 
thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 28: 
138-143. 
Janda S, Quon BS and Swiston J. (2010) HIV and pulmonary arterial hypertension: a 
systematic review. HIV Med 11: 620-634. 
Jarrett H and Barnett C. (2017) HIV-associated pulmonary hypertension. Curr Opin HIV AIDS 
12: 566-571. 
Jernigan NL, Walker BR and Resta TC. (2004) Endothelium-derived reactive oxygen species 
and endothelin-1 attenuate NO-dependent pulmonary vasodilation following chronic 
hypoxia. Am J Physiol Lung Cell Mol Physiol 287: L801-808. 
Jones J, Sullivan PS and Curran JW. (2019) Progress in the HIV epidemic: Identifying goals 
and measuring success. PLoS Med 16: e1002729. 
Kay JM, Harris P and Heath D. (1967) Pulmonary hypertension produced in rats by ingestion 
of Crotalaria spectabilis seeds. Thorax 22: 176-179. 
Lahm T, Tuder RM and Petrache I. (2014) Progress in solving the sex hormone paradox in 
pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 307: L7-26. 
Lan NSH, Massam BD, Kulkarni SS, et al. (2018) Pulmonary Arterial Hypertension: 
Pathophysiology and Treatment. Diseases 6. 
Liu T, Zhou HJ and Min W. (2017) ASK family in cardiovascular biology and medicine. Adv 
Biol Regul 66: 54-62. 
Mohapi BJ and Pitsoane EM. (2017) Life skills as a behaviour change strategy in the 
prevention of HIV and AIDS: Perceptions of students in an open and distance learning 
institution. Sahara j 14: 77-84. 
Morris A, Hillenbrand M, Finkelman M, et al. (2012) Serum (1-->3)-beta-D-glucan levels in 
HIV-infected individuals are associated with immunosuppression, inflammation, and 
cardiopulmonary function. J Acquir Immune Defic Syndr 61: 462-468. 
Nogueira-Ferreira R, Vitorino R, Ferreira R, et al. (2015) Exploring the monocrotaline animal 
model for the study of pulmonary arterial hypertension: A network approach. Pulm 
Pharmacol Ther 35: 8-16. 
Omland T, Sabatine MS, Jablonski KA, et al. (2007) Prognostic value of B-Type natriuretic 
peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll 
Cardiol 50: 205-214. 
Örem C. (2017) Epidemiology of pulmonary hypertension in the elderly. J Geriatr Cardiol 14: 
11-16. 
Piscoya Roncal CG, Mendes AA, Muniz MTC, et al. (2019) Schistosomiasis-associated 
pulmonary arterial hypertension: survival in endemic area in Brazil. Int J Cardiol Heart 
Vasc 25: 100373. 
Porter KM and Sutliff RL. (2012) HIV-1, reactive oxygen species, and vascular complications. 
Free Radic Biol Med 53: 143-159. 
Prins KW and Thenappan T. (2016) World Health Organization Group I Pulmonary 
Hypertension: Epidemiology and Pathophysiology. Cardiol Clin 34: 363-374. 
Rabinovitch M, Guignabert C, Humbert M, et al. (2014) Inflammation and immunity in the 
pathogenesis of pulmonary arterial hypertension. Circ Res 115: 165-175. 
20  
Rai MA, Pannek S and Fichtenbaum CJ. (2018) Emerging reverse transcriptase inhibitors for 
HIV-1 infection. Expert Opin Emerg Drugs 23: 149-157. 
Ranchoux B, Meloche J, Paulin R, et al. (2016) DNA Damage and Pulmonary Hypertension. 
Int J Mol Sci 17. 
Said SI. (2006) Mediators and modulators of pulmonary arterial hypertension. Am J Physiol 
Lung Cell Mol Physiol 291: L547-558. 
Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, et al. (2016) Pulmonary arterial 
hypertension: Basic knowledge for clinicians. Arch Cardiovasc Dis 109: 550-561. 
Scupinari T, Mannochio Russo H, Sabino Ferrari AB, et al. (2020) Crotalaria spectabilis as a 
source of pyrrolizidine alkaloids and phenolic compounds: HPLC-MS/MS dereplication 
and monocrotaline quantification of seed and leaf extracts. Phytochem Anal. 
Sierra-Aragon S and Walter H. (2012) Targets for inhibition of HIV replication: entry, enzyme 
action, release and maturation. Intervirology 55: 84-97. 
Simonneau G, Montani D, Celermajer DS, et al. (2019) Haemodynamic definitions and 
updated clinical classification of pulmonary hypertension. Eur Respir J 53. 
Smit M, Olney J, Ford NP, et al. (2018) The growing burden of noncommunicable disease 
among persons living with HIV in Zimbabwe. Aids 32: 773-782. 
Stein JH, Klein MA, Bellehumeur JL, et al. (2001) Use of human immunodeficiency virus-1 
protease inhibitors is associated with atherogenic lipoprotein changes and endothelial 
dysfunction. Circulation 104: 257-262. 
Studer SM and Gilkin RJ, Jr. (2014) Clinical trial designs in PAH: shifting from functional 
measurements to long-term clinical outcomes. Am J Manag Care 20: S115-122. 
Sydykov A, Mamazhakypov A, Petrovic A, et al. (2018) Inflammatory Mediators Drive 
Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential 
Biomarkers. Front Physiol 9: 609. 
Sztuka K and Jasinska-Stroschein M. (2017) Animal models of pulmonary arterial 
hypertension: A systematic review and meta-analysis of data from 6126 animals. 
Pharmacol Res 125: 201-214. 
Szturmowicz M, Kacprzak A, Blasinska-Przerwa K, et al. (2015) Pulmonary hypertension in 
the course of diffuse parenchymal lung diseases - state of art and future considerations. 
Pneumonol Alergol Pol 83: 312-323. 
Tilton JC, Amrine-Madsen H, Miamidian JL, et al. (2010) HIV type 1 from a patient with 
baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res 
Hum Retroviruses 26: 13-24. 
Umar S, Rabinovitch M and Eghbali M. (2012) Estrogen paradox in pulmonary hypertension: 
current controversies and future perspectives. Am J Respir Crit Care Med 186: 125-131. 
UNAIDS. (2019) Global HIV & AIDS statictics-2019 fact sheet. Available at: 
https://www.unaids.org/en/resources/fact-sheet. 
Weber M and Hamm C. (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in 








Oxidative stress and gene expression of antioxidants enzymes in monocrotaline-induced 








(Ref No: RESPNB-D-20-00161) 
22  
Oxidative stress and gene expression of antioxidants enzymes in monocrotaline-induced 









1Department of Human Physiology, School of Laboratory Medicine and Medical Sciences, 






Background: Pulmonary hypertension (PH) is a severe life-threatening pulmonary vasculopathy. 
Studies in animal models have identified the role of oxidative stress in PH. However, conflicting 
reports on the effects of antiretroviral medications. 
Aim: This study investigated the effects of zidovudine and /or ritonavir in the oxidative process 
of monocrotaline-induced PH in rats. 
 
Method: Forty male Sprague-Dawley rats weighing between 200 and 250 g were randomized 
into 5 different groups (n=8 per group). A single dose intraperitoneal injection of monocrotaline 
(60mg/kg) was administered to all the rats in four of the groups while the control group was 
excluded. There was daily oral administration of the antiretroviral medications-zidovudine 
(AZT)-only (100 mg/kg); ritonavir (RTV) only (30 mg/kg); AZT+ RTV (100+30 mg/kg); and 
the untreated group had equivalent volume of saline for 28 days respectively. The rats were 
euthanized by decapitation and the organs harvested at the end of the 28 days for analysis. Gene 
expression using RT-PCR for the antioxidants and laboratory assay for lipid peroxidation were 
analysed. 
 
Results: A significantly higher mRNA gene expression of catalase, superoxide dismutase, and 
glutathione peroxidase in the treated rats was observed compared to the untreated. There was an 
increase in malondialdehyde (MDA) in the heart tissues of untreated rats (37.01±1.16nmol/g, 
p<0.0001) compared to the control group (3.46±0.97 nmol/g) with an associated reduction in 
MDA by the antiretrovirals. Furthermore, an increase in the total antioxidant capacity (TAC) in 
AZT (0.85±0.02 nmol/g, p<0.0001), RTV (0.63±0.03 nmol/g, p<0.0001) and combination of 
AZT/RTV (0.77±0.06 nmol/g, p<0.0001) compared to untreated (0.28±0.03) rats. Oxidative 
stress with accompanied lipid peroxidation was observed in the experimental group without 
antiretroviral medications. The converse was observed in the groups treated with the 
antiretroviral medications, as there was a reduction in oxidative stress and evidence of lipid 
peroxidation. 
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Conclusion: Zidovudine and ritonavir ameliorate oxidative stress in experimental rats. Further 
studies are required to ascertain the role of oxidative stress in the reversal of established 
pulmonary hypertension by the administration of antiretroviral medications 
 





Pulmonary hypertension (PH) is a severe and life-threatening disease characterized by 
progressive vasculopathy and remodelling of pulmonary arteries leading to sustained pressure 
elevation in the pulmonary circulation (Sydykov et al., 2018). Pulmonary artery remodelling is 
vital in the development of pulmonary hypertension and right ventricular hypertrophy. This 
process involves oxidative reactions, mitochondrial injury, inflammation, and apoptosis (Chang 
et al., 2019). 
Oxidative stress is one of the identified factors, of the several complex processes, that culminate 
in the vascular remodelling towards the development and progression of PH (Sharma et al., 
2016). In which case, there is an imbalance in reactive oxygen species (ROS) handling due to 
either the over-production of ROS and/or decreased capability of antioxidant defenses. ROS 
causes vasoconstriction through smooth muscle cell contraction by triggering a rise in cytosolic 
free Ca2+ concentration (Aggarwal et al., 2013). Upregulation of ROS in the pathogenesis of PH 
has been reported in both animal models and humans with PH (Csiszar et al., 2009; Ghasemzadeh 
et al., 2014; Redout et al., 2010). Furthermore, the continuous elevation of ROS can also 
uncouple nitric oxide (NO) by an oxidative process resulting in either the production of 
superoxide (O2
•-) or conversion to peroxynitrite (ONOO−). These free radicals can reduce 
endothelial nitric oxide synthase and prostacyclin synthase leading to endothelial dysfunction, 
vasoconstriction and increased vascular tone which ultimately result in PH (Smukowska-Gorynia 
et al., 2019). 
HIV-associated PH (HIV-PH) is a recognized complication of HIV/AIDS, with a stable 
prevalence both before and following the introduction of antiretroviral drugs in the treatment of 
people living with HIV/AIDS (PLHIV). However, the reported prevalence of HIV-PH is known 
to be relatively higher in Africa than developed countries (Almodovar et al., 2011; Bigna et al., 
2015). The pathogenesis of HIV-PH remains unclear, as neither is there evidence that HIV infects 
pulmonary artery endothelial cells nor its proteins identified in significant amount in tissues 
during this process (Zuber et al., 2004). Furthermore, there is ambiguity in the role of the 
antiretroviral medications in the development and progression of the disease as some studies 
claim antiretroviral treatment decrease pulmonary arterial pressure (PAP). On the contrary, some 
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studies reported higher prevalence of HIV-PH in HIV/AIDS patients (Opravil et al., 1997; Zuber 
et al., 2004). Similarly, it has been observed that the use of zidovudine and indinavir in animal 
models may lead to PH through endothelin-1 production (Hebert et al., 2004). These 
antiretroviral medications have been linked with an increase in the production of reactive oxygen 
species (ROS) and endothelial mitochondrial dysfunction (Jiang et al., 2007). Nonetheless, 
zidovudine also has potent anti-inflammatory and antioxidant activities while protease inhibitors 
like ritonavir have demonstrated a protective role in animal model of HIV-PH (Gary-Bobo et al., 
2010; Liu et al., 2018). Likewise, several translational studies have shown the beneficial effect 
of antiretroviral medications on the risk reduction of HIV-PH and the variable outcomes among 
established early stage of HIV-PH patients (Pal et al., 2013; Quezada et al., 2012). This present 
study was conducted to unravel the critical role of antiretroviral medications-zidovudine and 
ritonavir, in the development of HIV-PH as it relates to oxidative stress in MCT-induced rat 
model of PH. Hence the study investigated the hypothesis that regular administration of 
antiretroviral medications in monocrotaline-treated rats ameliorates pulmonary hypertension via 
oxidative stress dependent mechanism. 
 




Animal experiment was approved by the Animal Research Committee of the University of 
KwaZulu-Natal, South Africa with the approval number AREC/066/018M. All experiments were 
conducted in accordance with the standard protocol and the ARRIVE guideline at the Biomedical 
Resource Centre in the University of KwaZulu-Natal, South Africa (Nam et al., 2018). Forty 
adult male Sprague Dawley rats (200–250 g) were housed at 18-22 °C under a 12-h light/12-h 
dark cycle with free access to food and water. 
 
Experimental design 
The forty adult male Sprague-Dawley rats were randomly assigned into five groups. One of the 
groups (n=8) served as the control while the remaining 32 rats were the PH model group that 
received a single 60 mg/kg intraperitoneal dose of MCT (Replamed, South Africa). Similarly, 
the rats in the control group were injected with the same volume of sterile saline. The rats in the 
treatment group were randomized into four subgroups (n=8 per group) and three of the four 
subgroups had daily administration of antiretroviral over a period of 4 weeks. The fourth was 
observed for same period although no other medication was administered as side the initial MCT. 
Following the MCT, rats in the treatment groups were dosed once daily on the antiretroviral 
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drugs of zidovudine (100mg/kg), ritonavir (30 mg/kg) or combination of both 
zidovudine/ritonavir (100mg/kg/30 mg/kg) or saline administration. 
 
Measurements of Oxidative Stress 
The heart and lung tissues were homogenized in ice-cold saline (0.9%) in a glass homogenizer. 
Then the homogenate was centrifuged at 2500 r/min for 10 min at 4 ◦C temperature. Supernatant 
of homogenate (10%, w/v) was employed for the subsequent tests. Total antioxidant capacity 
(TAC) activity was determined using the colorimetric assay. TAC determination (ElabScience, 
Biotechnology, MD, USA) was carried out following the manufacturer’s protocol. While 
malondialdehyde (MDA) assay (Oxis Research, Portland, OR, USA) was used by colorimetric 
quantification of MDA, as a lipid peroxidation marker. MDA concentration (µM) was measured 
at 532 nm and calculated using an MDA standard curve. The activities of MDA and TAC in the 
supernatant was determined according to the instructions of the respective testing kit (TAC assay 




The rats’ lungs and heart were harvested, immersed in 10% neutral buffered formalin, and 
embedded in paraffin. Tissues were sectioned at 4 μm, stained with hematoxylin and eosin 
(H&E), and analysed. A computerized morphometric system (Leica DM 500, Germany) was 
connected to a light microscopy for the assessment of the slides. The slides were evaluated by 
light microscopy at 400 x magnification, and the reviewers (AO, AN) who assessed the extent of 
vascular remodelling were blinded to the grouping. We randomly selected ten fields containing 
terminal arterioles (50–150 mm external diameters) and the dimensions of the external elastic 
lamina and the internal elastic lamina of each vessel were measured. The wall thickness (percent) 
of the arterioles were calculated using the formula as wall thickness (%) =100 x (1– internal 
elastic lamina/external elastic lamina). (Han et al., 2016). 
 
Quantitative real-time PCR 
Total RNA was isolated from the rat heart using TRIzol (Zymo Research), subsequently 
transcribed into cDNA and qPCR was performed. Primers for catalase (5’- 
CCTCAGAAACCCGATGTCCTG-3′ and 5’- GTCAAAGTGTGCCATCTCGTCG -3′), 
MnSOD (5’-ACCGAGGAGAAGTACCACGA-3′ and 5’- TAGGGCTCAGGTTTTGTCCAG - 
3′), GPX-1 (5’-TGAGAAGTGCGAGGTGAATG-3′ and 5’- CGGGGACCAAATGATGTACT- 
3′)          and          GAPDH          (5’-TGATTCTACCCACGGCAAGTT-3’          and          5’- 
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TGATGGGTTTCCCATTGATGA-3’) were purchased from Inqaba (South Africa). Primers for 
gene expression analysis were designed using published sequence information (Ren et al., 2019). 
PCR was performed in a 0.1 mL tube containing 2 µL cDNA, 1 µL (10 pmol) rat forward primer 
and reverse primer, 2 µL dNTP (1.25 mM each nucleotide), 5 µL SybrGreen, and 1µL dH2O. 
After denaturation at 95 ◦C for 10 min, the mixture underwent PCR for 40 cycles at 95 ◦C for 60 
s, annealing temperature for 60 s, and elongation at 72 ◦C for 60 s. The relative expression of 
protein mRNA level to GAPDH mRNA was calculated from cycle threshold (Cq) value by a 
ΔΔCq method and presented as relative to control. 
 
Drugs 
MCT was purchased from Replamed (South Africa), while zidovudine from Aspen Pharmacare 
Limited (Aspen, South Africa) and ritonavir from Abbvie Limited (Abbvie, South Africa). The 
dosage of the medications was based on previous studies involving rats (Adebiyi et al., 2015; 
Gary-Bobo et al., 2010). Of the major classes of antiretroviral drugs, NRTIs, which includes 
zidovudine, and protease inhibitors (PIs) like ritonavir have been the most widely implicated 
drug classes in development of endothelial dysfunction (Hansen et al., 2013). 
 
Statistical Analysis 
Statistical differences were analysed by one-way ANOVA with Tukey multiple comparison post- 
test. Data were recorded as mean ± SEM with P < 0.05 considered significant. All analyses were 
performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA). 
 
RESULTS 
Assessment on lipid peroxidation 
Figure 1 shows significant increase in the level of MDA in the heart tissues of experimental rats 
treated with MCT (37.01 ± 1.16 nmol/g, p <0.0001) compared to the rats in the control group 
(3.46 ± 0.97 nmol/g). The administration of zidovudine (8.80 ± 1.21 nmol/g, p <0.0001), ritonavir 
(8.47 ± 1.24 nmol/g, p <0.0001) and a combination of both drugs (9.18 ± 0.98 nmol/g, p <0.0001) 
was associated with mitigation of the effect of MCT by the reduction in the MDA levels in the 
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Figure 1: Level of lipid peroxidation in rat heart tissue 
Values are expressed as mean ± SEM (n=8/group). In comparison with the control: *P < 0.05 , 
**P < 0.01, ***P < 0.001 and ****P < 0.0001 while in comparison with MCT #P < 0.05, ##P < 
0.01, ###P < 0.001 and ####P < 0.0001. MCT + DRUG COMBO represents MCT plus Drug 
combination of zidovudine and ritonavir. 
 
 
Assessment of total antioxidant capacity 
As presented in figure 2, there was a significant difference in the total antioxidant capacity (TAC) 
of the heart tissue of the rats in the control group as compared to the treatment group exposed to 
only MCT, without any antiretroviral drugs given. A significant increase in TAC levels in the 
heart tissues of the rats treated with zidovudine (0.85 ± 0.02 nmol/g, P < 0.0001), ritonavir (0.63 
± 0.03 nmol/g, p < 0.0001) or a combination of both drugs (0.77 ± 0.06 nmol/g, p < 0.0001 was 
observed when compared to the group administered only  MCT (0.28 ± 0.03). 
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Figure 2: Total antioxidant capacity of the rat heart tissues 
Values are expressed as mean ± SEM (n=8/group). In comparison with the control: *P < 0.05 , 
**P < 0.01, ***P < 0.001 and ****P < 0.0001 while in comparison with MCT #P < 0.05, ##P < 
0.01, ###P < 0.001 and ####P < 0.0001. MCT + DRUG COMBO represents MCT plus Drug 





























combination of zidovudine and ritonavir. 
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Relative mRNA expression of superoxide dismutase in the rat heart tissue 
Figure 3 shows the relative mRNA expression of superoxide dismutase in the heart tissue of rats 
exposed to only MCT to be significantly lower (1.39 ± 0.14, p <0.0001) than the control group 
(6.02 ± 0.17). Figure 3 also revealed that MCT exposed animals treated with zidovudine (6.25 
± 0.26, p), ritonavir (5.78 ± 0.25, p <0.0001) and a combination of both drugs (6.45 ± 0.42, p 
<0.0001) expressed a significantly higher level of superoxide dismutase mRNA in comparison 
to the animals exposed to MCT without any treatment with antiretroviral drugs. 
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Figure 3: Relative mRNA expression of superoxide dismutase in the rat heart tissue 
Values are expressed as mean ± SEM (n=8/group). In comparison with the control: *P < 0.05 , 
**P < 0.01, ***P < 0.001 and ****P < 0.0001 while in comparison with MCT #P < 0.05, ##P < 
0.01, ###P < 0.001 and ####P < 0.0001. MCT + DRUG COMBO represents MCT plus Drug 
combination of zidovudine and ritonavir. 
 
Relative mRNA expression of catalase in the rat heart tissue 
The mRNA expression of catalase in the heart tissue of animals exposed to only MCT was 
significantly lower (0.91 ± 0.06, P <0.0001) than the control group (1.88 ±0.15, p <0.0001). It 
was also observed that MCT exposed animals treated with zidovudine (1.99 ± 0.09, p <0.0001 ), 
ritonavir (1.90 ± 0.02, p <0.0001) and a combination of both drugs (1.96 ± 0.04, p =0.0001) 
expressed a significantly higher level of catalase mRNA in comparison to the animals exposed 
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Figure 4: Relative mRNA expression of catalase in the heart tissue of experimental rats 
Values are expressed as mean ± SEM (n=8/group). In comparison with the control: *P < 0.05 , 
**P < 0.01, ***P < 0.001 and ****P < 0.0001 while in comparison with MCT #P < 0.05, ##P < 
0.01, ###P < 0.001 and ####P < 0.0001. MCT + DRUG COMBO represents MCT plus Drug 
combination of zidovudine and ritonavir 
 
Relative mRNA expression of glutathione peroxidase in the rat heart tissue 
Glutathione peroxidase mRNA expression in the heart of experimental animals exposed to MCT 
only (0.51 ± 0.17, p <0.0001) was significantly lower than that of the control group (2.255 ± 
0.16). The level of glutathione peroxidase mRNA expressed in MCT animals treated with 
zidovudine (2.35 ± 0.19, p <0.0001), ritonavir (2.06 ± 0.09, p < 0.0001) and a combination of 
both drugs (2.28 ± 0.19, p < 0.0001) was similar to that of the control group but it was 
significantly higher than the glutathione mRNA expressed in the heart of animals exposed to only 
MCT. 
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Figure 5: mRNA expression of glutathione peroxidase in the heart tissue of experimental rats 
Values are expressed as mean ± SEM (n=8/group). In comparison with the control: *P < 0.05 , 
































0.01, ###P < 0.001 and ####P < 0.0001. MCT + DRUG COMBO represents MCT plus Drug 
combination of zidovudine and ritonavir. 
 
 
Histological examination of the lung tissues of rats 
Histological examination of the slides under light microscope following H and E staining shows 
profound thickening in the media wall of the muscular pulmonary arteries in the lungs of rats 
treated with MCT. The arteries of rats treated with antiretroviral medications were thicker than 






Figure 6a: shows representative images of lung stained with H and E for the different groups 
(Image A- Control, Image B- MCT+Zidovudine, Image C- MCT+Ritonavir, Image D- 
MCT+Drugs combination of Zidovudine and Ritonavir and Image E- MCT) 
 
Figure 6b: shows arteriolar wall thickness in the different groups. In the treatment group with 
MCT shows significantly higher percentage wall thickness than the control (67.47 ± 1.22% 
versus 31.83 ± 1.09%, p < 0.0001). The anti-retroviral drug-zidovudine (41. 17 ± 0.52% versus 
67.47 ± 1.22%, P < 0.0001), drug-ritonavir (39.83 ± 0.32% versus 67.47 ± 1.22%, P < 0.0001) 
and a combination of drugs zidovudine and ritonavir (39.53 ± 0.84% versus 67.47 ± 1.22, p < 





Figure 6b shows wall thickness of pulmonary arterioles in lung tissues of experimental rats. 
Values are expressed as mean ± SEM (n=8/group). In comparison with the control: *P < 0.05 , 
**P < 0.01, ***P < 0.001 and ****P < 0.0001 while in comparison with MCT #P < 0.05, ##P < 
0.01, ###P < 0.001 and ####P < 0.0001. MCT + DRUG COMBO represents MCT plus Drug 
combination of zidovudine and ritonavir. 
 
DISCUSSION 
This study showed the effects of ARVs against MCT-induced PH. There was a reduction in MDA 
levels while there were increased levels in TAC, SOD, CAT and GPx. In addition, there was 
reduced thickness in the pulmonary arterioles of the lungs of MCT rats following the ARVs 
administration. 
In our study, the critical period of 28 days following the intraperitoneal administration of MCT 
was observed, as revealed in the literature, for the establishment of PH model in rats. However, 
beyond 28 days, at the single dose of 60 mg/kg of MCT, there is an increased likelihood of 
mortality of rats (Kishimoto et al., 2015). This finding was also observed in our study where the 
mortality was recorded in the experimental rats after the first 28 days. 
Similar to previous studies, the role of ROS in the development of PH following MCT 
administration but the effects of antiretroviral medication have not been explored. The mitigating 
effects of molecular hydrogen and several anti-ROS medications have been demonstrated to 
improve MCT-induced PH in rats (Ghasemzadeh et al., 2014; Kishimoto et al., 2015). The 
generation of ROS in monocrotaline-injected rats responsible for the development of PH results 
from the reduction in nitric oxide levels with the proliferation of pulmonary arterial smooth 
muscle cells, and ultimately enhanced pulmonary vasoconstriction and remodelling (Feng et al., 
2020; Wang et al., 2017). 
In the study, marked thickening in the pulmonary arteriolar media walls was observed on the 
histopathology results of the lungs in the MCT treated rats compared those treated on 
antiretroviral medications. This observed finding was like those reported in a previous study by 
33  
Lee et al. where prominent medial hypertrophy of the muscular pulmonary arteries was seen in 
MCT-induced PH rats (Lee et al., 2005). This structural change in the MCT treated rats when 
compared to the control and the rats that were administrated zidovudine and ritonavir could be 
explained by the mitigating effects of the antiretroviral medications on MCT treated rats. 
In animal models, increased MDA level has been reported in pulmonary hypertension compared 
to controls and the degree of elevation of MDA has been correlated with the disease severity 
(Chang et al., 2019; Irodova et al., 2002; Smukowska-Gorynia et al., 2019). This similar finding 
was observed in our study, as the heart tissues of rats exposed to MCT showed elevated levels of 
MDA, which was significantly mitigated by administration of zidovudine, ritonavir or both drugs 
in combination. This was likewise elucidated in the study by Feng et al., where an increased 
MDA level in MCT-induced pulmonary hypertension in rats revealed the administration of redox 
regulatory agent was protective against pulmonary hypertension (Feng et al., 2020). 
The overall balance between oxidant and antioxidants is reflected by the level of TAC which is 
an indicator of available enzymatic and no enzymatic antioxidant in a tissue (Smukowska- 
Gorynia et al., 2019). Our study found depletion in TAC in the MCT treated rats without 
antiretroviral therapy while higher TAC in the groups on the anti-retroviral drugs. 
The former three are the main enzymatic antioxidant system where the SODs catalysis the 
conversion of superoxide radical to H2O2 and catalase (CAT) further converts it into water. This 
activity can reverse pulmonary vascular remodelling and PH. Similar to our findings, 
significantly lower SOD mRNA expression has been reported in human and animal models (Mata 
et al., 2012; Masri et al., 2008). In animal models, MCT induces oxidative stress by 
downregulating the expression of genes responsible for mopping up free radicals, hence 
superoxide dismutase (SOD) preserves NO in vivo by scavenging superoxide and preventing the 
consumptive reactions (Masri et al., 2008). This present study also proves that pulmonary 
hypertension is associated with decreased expression of SOD mRNA especially in the MCT 
treated group. However, this finding further substantiated the treatment of MCT- induced 
pulmonary hypertension in rats with antiretroviral medications (zidovudine and ritonavir) 
ameliorated the depressive effect of MCT on SOD mRNA expression. 
The same was observed for the mRNA expression of CAT and GPX mRNA expression. MCT 
induced severe depression of GPX and CAT mRNA gene expression which was significantly 
mitigated by the administration of the anti-retroviral drug namely zidovudine and ritonavir. An 
imbalance in oxidative-antioxidative process in the blood vessel walls with increased reactive 
oxygen species produced by these cells result in vasoconstriction, smooth muscle cell 
proliferation, and vascular remodelling which if limited could help alleviate PH (Zhang et al., 
2019). 
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The findings from this study demonstrated that the antiretroviral drugs namely zidovudine, 
ritonavir or the combination of the two drugs ameliorated the distortion in the oxidant-antioxidant 
system in rats exposed to MCT. However, antiretroviral may not be sufficient as a sole therapy 
for HIV-PH, hence its combination with PH-specific therapy is of paramount importance. Further 
studies are also required to ascertain the role of oxidative stress following antiretroviral 
medications in the reversal of PH. 
To the best of our knowledge, this is the first study to demonstrate the effects of antiretroviral 
medications and oxidative stress as a biomarker in the development of PH in experimental 
animals. A limitation of our study is the non-pressure measurement by right heart catheterization 
which is an invasive procedure to establish an increased pressure in the right ventricle due to PH. 
However, the histologic examination of the media wall of pulmonary arteries was reviewed. 
 
Conclusion 
This study has demonstrated that MCT-induced PH generates ROS in rats and the protective role 
of antiretroviral drugs (zidovudine and ritonavir) in the treatment of PH. Therefore, this further 
support the beneficial role of antiretroviral drugs in the treatment of PH, but future research 
should be conducted to confirm these beneficial ARV effects in a HIV-PH model. 
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Background: Apoptosis resistance is a recognized pathogenetic mechanism in pulmonary 
hypertension (PH). However, the link between apoptosis signal-regulating kinase-1 (ASK-1) and 
PH is unclear. The present study was conducted to elucidate ASK-1 as a potential biomarker in 
PH. The study aimed to identify the role of ASK-1 in the mechanism of monocrotaline-induced 
PH in rats. 
Methods: Forty adult male Sprague-Dawley rats (body weight: 200-250 g) were randomly 
divided into five groups (n=8 per group). The treatment groups received a single intraperitoneal 
injection of MCT (60 mg kg-1) while the control group received an equivalent volume of 
intraperitoneal saline injection. Zidovudine (100 mg kg-1), ritonavir (30mg kg-1), or combination 
of both drugs (zidovudine 100mg kg-1 and ritonavir 30mg kg-1) were administrated daily for the 
study period of 28 days to the rats in three of the four groups with MCT for 28 days respectively. 
On the twenty-eight day of the study, rats were sacrificed, and organ harvested with the heart 
analyzed using RT-PCR for ASK-1. Antioxidant enzyme activities were determined using the 
colorimetric method. 
Results: Animal survival rate was one hundred percent in the treated and control groups while 
the untreated group recorded 62% survival rate. There was significantly lower mRNA gene 
expression of ASK-1 in the heart of the treated rats with zidovudine (2.67 ± 0.09, p < 0.0001), 
ritonavir (2.57 ± 0.11, p < 0.0001) and a combination of both (2.75 ± 0.06, p < 0.0001) when 
compared to rats in the untreated group. An overexpressed mRNA gene of ASK-1 in the 
untreated rats (12.0 ± 0.90, p < 0.0001) when compared to the control. 
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Conclusion: ASK-1 is a veritable biomarker for anti-apoptotic characteristics of PH. Our 
findings will spur new investigations on the role of ASK-1 in PH and the potential therapeutic 
benefits of antiretroviral medications in the prevention of PH. 




Pulmonary hypertension (PH) is a fatal progressive disease involving an increase in pulmonary 
vascular resistance and pulmonary arterial pressure (PAP) which leads to right ventricular (RV) 
dysfunction, right heart failure and ultimately death (Zhang et al., 2017; Varshney et al., 2016). 
It involves vascular endothelial dysfunction, chronic inflammation, smooth muscle cell 
proliferation, pulmonary arteriolar occlusion, apoptosis resistance, and the hallmark feature of 
pulmonary vascular remodelling (Zhang et al., 2019; Cai et al., 2018). During this process, the 
pulmonary vascular pathology evolves from an inert state to pro-proliferative, apoptotic-resistant 
vascular cells (Gamen et al., 2016). 
Apoptosis signal-regulating kinase-1 (ASK-1) is an upstream kinase in the p38 mitogen-activated 
protein kinases (MAPKs) signalling pathway that respond to stimuli by activating cellular 
proliferation, differentiation, survival, apoptosis, and inflammation (Qin et al., 2016; Tesch et 
al., 2015). Its inhibition has been associated with decline in vascular remodelling in MCT- 
induced PH experimental rats however the contrary is observed when activated (Qin et al., 2016; 
Budas et al., 2018). The activation of apoptotic pathway by the continuous induction of ASK-1 
induces mitochondria-dependent caspases, triggering the intrinsic apoptosis pathway which 
regulates programmed cell death (Tesch et al., 2015). ASK-1 is activated in response to several 
stimuli most especially to oxidative stress and it is widely expressed in diverse tissues like heart 
and lungs (Courboulin et al., 2011; Tesch et al., 2015). 
Human immunodeficiency virus infection is a known risk for the development of severe PH, 
however, the prevalence of HIV associated PH (HIV-PH) has remained stable from the pre-anti- 
retroviral therapy era (Opravil and Sereni, 2008). The impact of antiretroviral medications on the 
development of PH is controversial, however, nucleoside reverse transcriptase inhibitors (NRTI) 
and protease inhibitors like zidovudine and ritonavir respectively have been reported to improve 
outcome and survival of HIV-PH (Pugliese et al., 2000; Gary-Bobo et al., 2010). Animal models 
of PH have been developed, following the administration of monocrotaline and other techniques, 
which gives a good representation of the expected findings in humans (Nogueira-Ferreira et al., 
2015). Using this modality to explore the effects of anti-retroviral therapy on the development 
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of PH with the aim of identifying potential biomarker would give clarity to the pathogenesis of 
PH. 
Despite the current therapeutic advances such as endothelin-1 receptor blockers, type 5 
phosphodiesterase inhibitors or platelet derived growth factors (PDGF) receptor blockers in the 
management of PH, no available literature has explored the role of antiretroviral medications in 
the development of PH using ASK-1 as a biomarker (Courboulin et al., 2011). The study aimed 
at investigating the effect of antiretroviral medication on ASK-1 in monocrotaline-induced PH 
in rats. 
 
MATERIALS AND METHODS 
Animals 
Forty adult male Sprague Dawley rats (weighing 200-250 g) were supplied by the Biomedical 
Resource Unit of the University of KwaZulu-Natal, South Africa, and allowed to acclimatize for 
one week before commencement of the experiments. All the rats were housed in standard cages 
under standard laboratory conditions of 18-22 oC room temperature, 50-70% humidity and 12 
hours light/dark cycle with ad libitum access to dry feed and water. Animal experiment was 
approved by the Animal Research Ethics Committee of the institution (AREC/066/018M) and 
the use of rats complied with the 3R guidelines (3R: Replace, reduce, and refine) for the use of 
experimental animals (Nam et al., 2018). 
 
Experimental design 
The 40 rats were randomly assigned into five groups (n=8), while the treatment groups received 
a single intraperitoneal injection of monocrotaline (MCT) at the dose of 60 mg. kg-1), the control 
group received equivalent volume of intraperitoneal saline injection. MCT (Replamed, South 
Africa) was dissolved in 1N HCl and buffered to pH 7.0 with 1N NaOH before injection. 
Subsequently, a daily dose of zidovudine (100mg. kg-1), ritonavir (30 mg. kg-1) and combination 
of each zidovudine/ritonavir was administered to rats in three of the four treatment groups 
respectively for 28 days. 
RNA extraction and measurement by RT-quantitative PCR. 
Total RNA was extracted from lung tissues using Trizol (Zymo research) agent. Quantitative 
real-time RT-PCR (qPCR) was performed to assess mRNA expression of the following genes. 
The primer for the genes were as follows: ASK-1 (FW, 5’-TGAATCTGAGCCAACACTACAG- 
3’ and RV, 5’-CATCAGCAAGCACGTGCCAAA-3’), GAPDH (FW, 5’- 
TGATTCTACCCACGGCAAGTT-3’    and    RV,    5’-TGATGGGTTTCCCATTGATGA-3’) 
which were purchased from Inqaba (South Africa). This primer for gene expression was designed 
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using published sequence information from previous related study (Kherrouche et al., 2006). 
PCR Detection System (BioRad Co., CA, USA) was employed to execute Real-Time Polymerase 
Chain Reaction (PCR) with 0.1 mL tube containing 2 µL cDNA, 2 µL dNTP ( 1.25 mM each 
nucleotide), 1 µL reverse and forward primer, 1 µL dH20 and 5 µL SYBRGreen . The PCR 
conditions were as follows: 10 min at 95 °C, followed by 40 cycles of 60 s at 95 °C, 30 s at 
annealing temperature, and 60 s at 72 °C. We verified the specificity of PCR by measuring the 
melting curve of the PCR products at the end of the reaction. Fluorescence data were specified 
for collection during primer extension. The relative expression of mRNA to GAPDH mRNA was 
calculated from the cycle threshold (Cq) value by a delta delta quantification cycle (∆∆Cq) 
method and presented as a relative to control (Coates et al., 2017). 
 
Histomorphometric analysis 
The harvested lung and heart tissues were placed with 10% formalin, embedded at 4℃ in 
paraffin, and sliced to a thickness of 4 μm. Subsequently, the sections were stained with the 
hematoxylin staining method for 5 min, washed under running water for 1 min, dissimilated 30 
s in hydrochloric acid ethanol, and immersed in tap water for 15 min or warm water (about 50℃) 
for 5 min. Sections were stained for 2 min this time with eosin, each section was mounted with 
DPX and a coverslip. The histological changes were observed under an optical microscope (Leica 
DM 500, Germany). Ten fields containing terminal arterioles (50–150 mm external diameters) 
were randomly selected and the dimensions of the external elastic lamina and the internal elastic 
lamina of each vessel were measured. The wall thickness (percent) of the arterioles were 
categorized depending on the degree of vascular muscularization as 1–3, of which: 1=no 
muscularization, not occluded; 2=partial muscularization, not fully occluded; 3=muscularization, 
fully occluded(Han et al., 2016). 
Drugs 
MCT (Sigma-Aldrich, St. Louis, MO, USA) was purchased from Replamed, SA. Zidovudine 
was obtained from Aspen Pharmacare Limited (Aspen, South Africa) while ritonavir was 
obtained from Abbvie Limited (South Africa). Previous animal studies involving rats were used 
as template for the dosage of the medications (Gary-Bobo et al., 2010; Adebiyi et al., 2015). 
Data Analysis 
Data analysis was performed using one-way ANOVA for statistical differences with Tukey post- 
hoc tests. Differences for all tests were considered significant when the P value was <0.05 and 
data recorded as mean ± standard error of mean (SEM). All the analyses were performed using 
GraphPad Prism, version 6 (GraphPad, San Diego, CA, USA) 
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RESULTS 
Animal survival rate 
All rats survived the 1-, 2-, and 3-week and rats in the control and treated groups remained active 
even till the end of the study. In contrast, three rats in the group treated with MCT only, died in 
the 4th week of the study on days on days 23 and 25 with 38% death rate at the end of the 
experiment (p = 0.0097). During the study, none of the rats in the control group (unexposed) died 
as well as those on antiretroviral medication viz a viz zidovudine and ritonavir or a combination 




















Figure 1: Survival rate of the experimental animals within 28 days. Values are expressed as 
percent survival. 
 
Relative organ weight 
There was no significant difference (p = 0.3165) in the relative heart weights (RHW) of rats 
across all groups: control (0.38 ± 0.02%), MCT (0.31 ± 0.01%), MCT and zidovudine (0.48 ± 
0.03%), MCT and ritonavir (0.41 ± 0.02%) and MCT and a combination of zidovudine and 
ritonavir (0.43 ± 0.01%). 
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Figure 2: Relative heart weight (RWH) of the experimental animals 
Values are expressed as mean ± standard error of mean (SEM). 
Assessment on the relative mRNA expression of ASK-1 in rat heart 
Figure 3 shows an overexpression of ASK-1 in the heart tissue of only MCT treated rats (12.0 ± 
0.90, p < 0.0001) when compared to the rats in the control group. The mRNA expressions in the 
hearts of rats with zidovudine (2.67 ± 0.09, p < 0.0001), ritonavir (2.57 ±0.11, p < 0.0001) and a 
combination of both (2.75 ± 0.06, p < 0.0001) were lower and statistically significant when 
compared to rats in the untreated group. Likewise, the mRNA expression of ASK-1 was similar 
to the control rats (2.22 ± 0.08) but not statistically significant. 
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Figure 3: Relative mRNA expression of ASK-1 in the heart tissue of experimental rats 
Values are expressed as mean ± standard error of mean (SEM). In comparison with the control, 
*P <0.05, **P < 0.01, ***P < 0.0001 while in comparison with MCT #P <0.05, ##P <0.01, ###P 
<0.001, ####P < 0.0001. MCT + DRUG COMBO represents MCT plus a combination of 



























The light microscope examination of the slides with representative pictorial features shows 
marked thickening in the media walls of the muscular pulmonary arteries in the lungs of the 
untreated rats following MCT administration. The rats with anti-retroviral drugs (zidovudine, 
ritonavir and both drugs combined) show significant improvement in their media wall thickness 





Figure 4a-Representative images of lung stained with H and E for the different groups (Image 
A- Control, Image B- MCT+Drug A, Image C- MCT+Drug B, Image D- MCT+Drugs combo 
and Image E- MCT) 
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Figure 4b shows degree of pulmonary arterioles muscularization in lung tissues of experimental 
rats. 
1= Nonmuscularization 
2= Partial muscularization 
















In this study, there was a reduction in the animal survival rate in the only MCT treated group but 
no significant difference in the relative heart weight in the experimental groups. Our study 
showed a significantly lower mRNA gene expression of ASK-1 in the heart tissues of the treated 
rats when compared to rats in the untreated group as well as an overexpressed mRNA gene of 
ASK-1 in the untreated rats relative to the control. 
The survival rate of the untreated rats dropped to 87.0% on day 23 which further declined to 
62.0% by day 25. This reduction in the animal survival rate of untreated rats after the three weeks 
was similar to previous studies where survival rates of 70% to 90% was observed by the 21st 
days following MCT injection (Itoh et al., 2004; Nagaya et al., 2003). As observed in our study 
and previous studies, rats were reported to have died after the third week of MCT administration 
in the untreated rats. This findings could be due to the manifestations of PH in the rats due to the 
MCT and this has been reported to be maximum after this period (Ruiter et al., 2013). Therefore, 
the therapeutic effects of the antiretroviral in the prevention of mortality among the rats in the 
treatment would suggest its beneficial role in mitigating the development of PH in these groups. 
In our study, the ASK-1 mRNA gene expression in the treated rats was higher compared to the 
control rats but lower than in the untreated rats. This agreed with previous studies where ASK-1 
stimulation of cellular apoptotic response plays a major role in the signalling pathways and 
treatment modalities (Kolliputi and Waxman, 2009; Kherrouche et al., 2006). ASK-1 is 
fundamental to programmed cell death, of which its failure affects apoptosis, and its inhibition 
reduced pathological remodelling of the pulmonary vasculature and the right ventricle and this 
progresses to pulmonary hypertension in rodent models(Xu et al., 2016). 
In a similar study involving monocrotaline-induced pulmonary hypertension in rats, the 
overexpression of ASK-1 mRNA gene in the untreated rats in relation to the control group could 
be evidence of the ASK-1 resistance which is anti-apoptotic (Budas et al., 2018). Such 
presentations of apoptosis-resistant could manifest as increased proliferative vascular changes of 
the endothelial cells (EC) thereby obliterating the vessels due to the anti-apoptotic effects (Suzuki 
et al., 2016). 
The histopathology results of the lungs revealed marked thickening in the media walls of the 
muscular pulmonary arteries in the untreated rats. However, improvement in this media wall 
thickness was observed in the rats treated with zidovudine and or ritonavir following the MCT- 
induced PH. This histologic finding is comparable to those reported prominent medial 
hypertrophy of the muscular pulmonary arteries in MCT-induced PH rats (Lee et al., 2005). This 
is an indication that zidovudine, ritonavir, and a combination of both drugs were able to mitigate 
the deteriorative effects of MCT. 
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In conclusion, this research indicates that zidovudine and ritonavir attenuate MCT-induced PH 
in rats by down-regulation of ASK-1 which plays a major role in the anti-apoptotic characteristics 
in the development of PH. 
 
Abbreviations CTRL: Control; Combo: Combination; HIV: Human immunodeficiency virus; 
MCT: Monocrotaline; PH: Pulmonary hypertension; RV: Right ventricle; S: Septum; SEM: 
Standard error of the mean. 
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ROS are reactive chemical species containing oxygen which include molecules such as 
superoxide anion (O2
•−), hydrogen peroxide (H2O2), and the hydroxyl radical (HO
•) (Pan et al., 
2010). They play a vital role in the regulation of biological processes such as cell proliferation, 
differentiation, apoptosis, and cellular senescence which are important in aging, cancer and 
pulmonary vascular diseases (Finkel, 2003; Rana, 2008). 
Apoptosis (programmed cell death) is a strictly controlled process in which cells undergo auto- 
destruction due to DNA damage, senescence, inflammation or oxidative stress (Kerr et al., 1972). 
The regulation of apoptosis is crucial for the maintenance of normal cellular homeostasis; 
however, the deregulation of apoptosis has been linked to several pathologies (Fulda et al., 2010). 
Oxidative stress which results from an imbalance in the concentration of pro-oxidants which are 
ROS and antioxidant within cells, is majorly stimulated by apoptosis. Reactive oxygen 
containing molecules such as H2O2 can cause the release of cytochrome c from mitochondria into 
the cytosol and also activate nuclear transcription factors, like NF-κB, AP-1, and p53 and other 
proteins or genes which are also involved in the apoptotic pathway. Similarly, nitric oxide has 
been reported to induce apoptosis by increasing ceramide generation through caspase-3 
activation, induction of mitochondrial permeability transition, and activation of the Fas system 
(Denning et al., 2002). 
ASK-1 is one of the ROS-regulated inducers of apoptosis. It is a member of the MAP3K family 
of protein kinases that could regulate a wide range of physiological processes ranging from cell 
proliferation, differentiation and apoptosis (Ichijo et al., 1997; Takeda et al., 2011; Tobiume et 
al., 2001). Oxidative stress induces ASK-1-dependent production of inflammatory cytokines 
such as tumour necrotic factor-α, interleukin-6, and interleukin-1β which are necessary for 
apoptosis (Nakagawa et al., 2011). Although ASK-1 is abundant in the cells, but it is usually 
repressed by thiol-containing antioxidant proteins in the cytosol and mitochondria. Furthermore, 
the liberal production of ROS could overwhelm the anti-oxidant defence system resulting in 
oxidative stress and the activation of ASK-1(Budas et al., 2018; Saitoh et al., 1998). 
 
There is increasing evidence within the literature that ROS contribute significantly to apoptosis 
and ultimately play a vital role in the pathophysiology of PH (Xu et al., 2011; Matsuzawa et al., 
2005). Our study demonstrated an increased oxidative stress with accompanied lipid peroxidation 
in the untreated group (without antiretroviral medications). On the contrary, the treated group 
showed a reduction in oxidative stress and evidence of lipid peroxidation. Lipid peroxidation has 
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been implicated in studies as a mediator in the development of PH as therapy against lipid 
peroxidation has been found effective in the treatment of PH (Mohammadi et al., 2012). Similar 
to previous studies, the higher MDA levels were found in PH compared to the control and the 
treated groups (Wen et al., 2019; Jin et al., 2008). On the contrary, Awodele et al. found a non- 
significant decrease in the MDA level of zidovudine treated rats when compared with other 
groups which could be due to the lower dose of zidovudine and the combination of the 
antiretroviral with antituberculosis drugs in their study (Awodele et al., 2011). 
 
The finding of decreased lipid peroxidation marker MDA in rats and an accompanying elevated 
TAC in the antiretroviral treated MCT-induced pulmonary hypertension rats supports the unlikely 
development of PH. Hence the treatment with zidovudine and/or ritonavir ameliorated these 
oxidative stress indices. The level of TAC was lowest in the untreated rats compared to the control 
and treated groups. This decrease in TAC in our study is similar to findings in other related 
studies where low TAC is reported in untreated animal groups (Liu et al., 2019). ROS enhances 
endothelin-1 production and down-regulation of eNOS expression leading to PH (Fulton et al., 
2017). 
 
An upregulation of ASK-1 gene would result in uncontrolled activity in the ASK-1-p38 
pathway and ultimately results in apoptosis. Our study also revealed that pulmonary 
hypertension induced by MCT in rats heart tissues of rats significantly increased the expression 
of ASK-1 when compared with the control group. The administration of antiretroviral drugs 
(zidovudine and/or ritonavir) significantly reduced oxidative stress induced by exposure to 
MCT and resulted in the downregulation of ASK-1 mRNA expression. The reversal of MCT- 
induced oxidative stress and ASK-1 overexpression by the anti-retroviral drugs as observed 
could be due to an unexplained interplay of actions of the MCT and antiretroviral although 
other studies has associated most anti-retroviral drugs to oxidative stress (Manda et al., 2011; 
Sharma, 2014; Williams et al., 2017). This is not surprising as it has been elucidated that 
reduced levels of antioxidants results in the continued activation on ASK-1 (Budas et al., 2018; 
Saitoh et al., 1998) 
 
4.2 Conclusion 
Our study demonstrated that the antiretroviral drugs namely zidovudine, ritonavir or the 
combination of the two drugs ameliorated the distortion in the oxidant-antioxidant system in 
rats exposed to MCT. However, antiretroviral may not be sufficient as a sole therapy for HIV- 
PH, hence its combination with PH-specific therapy is of paramount importance. Further 
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studies are also required to ascertain the role of oxidative stress following antiretroviral 
medications in the reversal of PH. 
 
4.3 Limitations 
A limitation of our study is the non-pressure measurement by right heart catheterization which 
is an invasive procedure to establish an increased pressure in the right ventricle due to PH. 
 
4.4 Recommendation 
The data from this research further highlights the need to explore the use of ASK-1 as a 
biomarker for the anti-apoptotic characteristics of PH. Although the antiretroviral medications 
ameliorated the distortion in the oxidant-antioxidant system in rats exposed to MCT. It may not 
be sufficient as a sole therapy for HIV-PH, hence its combination with PH-specific therapy 
could be paramount to the understanding of this disease entity. Further studies are also required 
to ascertain the role of inflammatory cytokines such as tumour necrotic factor -α, interleukin-6, 
and interleukin-1β in ROS-ASK-1 linkage. 
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